TPP0010,O
.1177,NUMBER
/,O
2045125320935306Therapeutic,O
Advances,O
in,O
Psychophar,O
‐,O
macologyD,O
Bishara,PERSON
.,O
C,O
Kalafatis,O
Therapeutic,O
Advances,O
in,O
Psy,O
‐,O
chopharmacology,O
Emerging,O
and,O
experimental,O
treatments,O
for,O
COVID,O
‐,O
19,NUMBER
and,O
drug,O
interactions,O
with,O
psychotropic,O
agents,O
Delia,PERSON
Bishara,PERSON
Ther,PERSON
Adv,O
Psychopharmacol,O
.,O
Chris,PERSON
Kalafatis,PERSON
and,O
David,PERSON
Taylor,PERSON
Abstract,O
:,O
As,O
yet,O
.,O
no,O
agents,O
have,O
been,O
approved,O
for,O
the,O
treatment,O
of,O
COVID,O
‐,O
19,NUMBER
.,O
although,O
several,O
experimental,O
drugs,CRIMINAL_CHARGE
are,O
being,O
used,O
off,O
licence,O
.,O
These,O
may,O
have,O
serious,O
adverse,O
agents,O
being,O
used,O
across,O
the,O
world,O
for,O
the,O
treatment,O
of,O
COVID,O
‐,O
19,NUMBER
and,O
investigated,O
their,O
drug,O
interaction,O
potential,O
with,O
psychotropic,O
agents,O
using,O
several,O
drug,O
interaction,O
databases,O
and,O
resources,O
.,O
A,O
preliminary,O
search,O
identified,O
the,O
following,O
drugs,CRIMINAL_CHARGE
as,O
being,O
used,O
to,O
treat,O
COVID,O
‐,O
19,NUMBER
symptoms,O
:,O
atazanavir,O
(,O
ATV,O
),O
.,O
azithromycin,O
(,O
AZI,O
),O
.,O
chloroquine,O
(,O
CLQ,O
),O
/,O
hydroxychloroquine,O
(,O
HCLQ,O
),O
.,O
dipyridamole,O
.,O
famotidine,O
(,O
FAM,O
),O
.,O
favipiravir,O
.,O
lopinavir,O
/,O
ritonavir,O
(,O
LPV,O
/,O
r,O
),O
.,O
nitazoxanide,O
.,O
remde,O
‐,O
sivir,O
.,O
ribavirin,O
and,O
tocilizumab,O
.,O
Many,O
serious,O
adverse,O
effects,O
and,O
potential,O
drug,O
interactions,O
with,O
psychotropic,O
agents,O
were,O
identified,O
.,O
The,O
most,O
problematic,O
agents,O
were,O
found,O
to,O
be,O
ATV,O
.,O
AZI,O
.,O
CLQ,O
.,O
HCLQ,O
.,O
FAM,O
and,O
LPV,O
/,O
r,O
in,O
terms,O
of,O
both,O
pharmacokinetic,O
as,O
well,O
as,O
serious,O
pharmacodynamic,O
drug,O
interactions,O
.,O
including,O
QTc,O
prolongation,O
and,O
neutropenia,O
.,O
Significant,O
caution,O
should,O
be,O
ex,O
‐,O
ercised,O
if,O
using,O
any,O
of,O
the,O
medications,O
being,O
trialled,O
for,O
the,O
treatment,O
of,O
COVID,O
‐,O
19,NUMBER
until,O
robust,O
clinical,O
trial,O
data,O
are,O
avail,O
‐,O
able,O
.,O
An,O
even,O
higher,O
threshold,O
of,O
vigilance,O
should,O
be,O
maintained,O
for,O
patients,O
with,O
pre,O
‐,O
existing,O
conditions,O
and,O
older,O
adults,O
due,O
to,O
added,O
toxicity,O
and,O
drug,O
interactions,O
.,O
especially,O
with,O
psychotrop,O
‐,O
ic,O
agents,O
.,O
Keywords,O
:,O
adverse,O
effects,O
.,O
drug,O
‐,O
interactions,O
.,O
psy,O
‐,O
chotropic,O
drugs,CRIMINAL_CHARGE
.,O
treatment,O
COVID,O
‐,O
19,NUMBER
Although,O
no,O
treatments,O
have,O
been,O
approved,O
or,O
shown,O
to,O
be,O
safe,O
and,O
effective,O
for,O
the,O
treatment,O
of,O
COVID,O
‐,O
19,NUMBER
.,O
there,O
are,O
several,O
treatments,O
being,O
used,O
off,O
licence,O
either,O
on,O
a,O
compassionate,O
‐,O
use,O
basis,O
or,O
as,O
part,O
of,O
a,O
randomised,O
controlled,O
trial,O
.,O
The,O
South,LOCATION
London,CITY
and,O
Maudsley,ORGANIZATION
NHS,ORGANIZATION
Foundation,ORGANIZATION
Trust,O
does,O
not,O
currently,DATE
recommend,O
initiating,O
these,O
drugs,CRIMINAL_CHARGE
.,O
Howev,O
‐,O
er,O
.,O
clinicians,O
need,O
to,O
be,O
aware,O
of,O
their,O
adverse,O
effects,O
and,O
po,O
‐,O
tential,O
drug,O
interactions,O
with,O
psychotropic,O
agents,O
in,O
case,O
they,O
are,O
prescribed,O
elsewhere,O
to,O
patients,O
from,O
our,O
services,O
.,O
Serious,O
adverse,O
effects,O
are,O
associated,O
with,O
these,O
drugs,CRIMINAL_CHARGE
.,O
and,O
these,O
may,O
overlap,O
with,O
the,O
clinical,O
manifestations,O
of,O
COVID,O
‐,O
19,NUMBER
.,O
Chloroquine,O
(,O
CLQ,O
),O
/,O
hydroxychloroquine,O
(,O
HCLQ,O
),O
.,O
azithromycin,O
(,O
AZI,O
),O
.,O
and,O
lopinavir,O
/,O
ritonavir,O
(,O
LPV,O
/,O
r,O
),O
are,O
associated,O
with,O
a,O
range,O
of,O
ad,O
‐,O
verse,O
effects,O
.,O
including,O
QTc,O
prolongation,O
.,O
torsade,O
de,O
pointes,O
.,O
hepatitis,O
.,O
acute,O
pancreatitis,CAUSE_OF_DEATH
and,O
neutropenia,O
.1,NUMBER
Considering,O
that,O
most,O
patients,O
who,O
have,O
died,O
from,O
COVID,O
‐,O
19,NUMBER
were,O
elderly,O
and,O
had,O
underlying,O
health,O
conditions,O
including,O
cardiovascular,O
comorbidi,O
‐,O
ties,O
.,O
CLQ,O
/,O
HCLQ,O
.,O
AZI,O
.,O
and,O
LPV,O
/,O
r,O
could,O
potentially,O
increase,O
the,O
risk,O
of,O
cardiac,O
death,O
.,O
In,O
addition,O
.,O
hepatitis,O
and,O
leucopoenia,O
are,O
clinical,O
manifestations,O
of,O
COVID,O
‐,O
19,NUMBER
.,O
and,O
so,O
the,O
use,O
of,O
these,O
drugs,CRIMINAL_CHARGE
could,O
worsen,O
both,O
hepatic,O
and,O
bone,O
marrow,O
dysfunction,O
.,O
It,O
would,O
also,O
be,O
almost,O
impossible,O
to,O
differentiate,O
the,O
drug,O
‐,O
related,O
adverse,O
effects,O
from,O
the,O
disease,CAUSE_OF_DEATH
manifestations,O
.1,NUMBER
Correspondence,O
to,O
:,O
Delia,PERSON
Bishara,PERSON
Maudsley,PERSON
Hospital,PERSON
.,O
Denmark,COUNTRY
Hill,LOCATION
.,O
Camberwell,O
.,O
London,CITY
SE5,O
Chris,PERSON
Kalafatis,PERSON
David,PERSON
Taylor,PERSON
South,LOCATION
London,CITY
and,O
Maudsley,PERSON
NHS,ORGANIZATION
Foundation,ORGANIZATION
Trust,ORGANIZATION
.,O
London,CITY
.,O
UK,COUNTRY
Several,O
clinical,O
trials,O
are,O
cur,O
‐,O
rently,O
underway,O
.,O
The,O
World,ORGANIZATION
Health,ORGANIZATION
Organisation,ORGANIZATION
and,O
its,O
partners,O
have,O
launched,O
the,O
Solidarity,ORGANIZATION
trial,O
.2,O
a,O
large,O
international,O
study,O
to,O
compare,O
different,O
treatments,O
and,O
ensure,O
Therapeutic,O
Advances,O
in,O
Psychopharmacology,O
10,NUMBER
clear,O
evidence,O
of,O
which,O
treatments,O
are,O
most,O
effective,O
.,O
The,O
study,O
will,O
have,O
five,NUMBER
arms,O
:,O
standard,O
of,O
Oxford,CITY
have,O
launched,O
the,O
Recovery,O
trial,O
.3,O
which,O
will,O
be,O
testing,O
some,O
of,O
these,O
suggested,O
treatments,O
:,O
LPV,O
/,O
r,O
.,O
low,O
‐,O
dose,O
dexamethasone,O
.,O
HCLQ,O
and,O
inhaled,O
IFN,O
‐,O
beta1a,O
.,O
main,O
experimental,O
drugs,CRIMINAL_CHARGE
that,O
are,O
being,O
trialled,O
or,O
used,O
off,O
licence,O
to,O
treat,O
patients,O
with,O
COVID,O
‐,O
19,NUMBER
.,O
For,O
each,O
drug,O
we,O
aimed,O
to,O
examine,O
trial,O
outcome,O
data,O
.,O
dosing,O
reg,O
‐,O
imens,O
.,O
adverse,O
effects,O
.,O
drug,O
interaction,O
potential,O
and,O
specific,O
drug,O
interactions,O
with,O
commonly,O
used,O
psychotropic,O
agents,O
in,O
the,O
United,COUNTRY
Kingdom,COUNTRY
(,O
UK,COUNTRY
),O
.,O
A,O
preliminary,O
search,O
identified,O
several,O
drugs,CRIMINAL_CHARGE
that,O
were,O
being,O
used,O
off,O
licence,O
around,O
the,O
world,O
for,O
the,O
treatment,O
of,O
COVID,O
‐,O
19,NUMBER
either,O
as,O
part,O
of,O
a,O
clinical,O
trial,O
or,O
on,O
a,O
compassionate,O
basis,O
.,O
For,O
each,O
potential,O
adverse,O
effects,O
.,O
We,O
then,O
used,O
the,O
following,O
drug,O
‐,O
interaction,O
databases,O
and,O
on,O
‐,O
line,O
re,O
‐,O
sources,O
to,O
identify,O
potential,O
drug,O
interactions,O
with,O
the,O
commonly,O
used,O
psychotropic,O
agents,O
in,O
the,O
UK,COUNTRY
:,O
Stockleys,O
Drug,O
Interactions,O
Checker,TITLE
.,O
human,O
immunodeficiency,O
virus,O
(,O
HIV,CAUSE_OF_DEATH
),O
drug,O
interactions,O
website,O
.,O
drug,O
interaction,O
checker,TITLE
.,O
the,O
Drugbank,O
and,O
the,O
Liverpool,ORGANIZATION
Drug,MISC
Interactions,MISC
Adverse,MISC
effects,O
.,O
ATV,O
can,O
cause,O
serious,O
.,O
lifethreatening,O
adverse,O
effects,O
.,O
including,O
heart,O
rhythm,O
abnormal,O
‐,O
ities,O
.,O
severe,O
rash,O
and,O
hepatic,O
disorders,O
.,O
as,O
well,O
as,O
life,O
‐,O
threat,O
‐,O
ening,O
drug,O
interactions,O
.,O
Drug,O
interactions,O
.,O
ATV,O
is,O
metabolised,O
principally,O
by,O
cytochrome,O
P450,O
(,O
CYP,O
),O
3A4,O
.,O
It,O
is,O
an,O
inhibitor,O
of,O
CYP3A4,O
and,O
a,O
weak,O
inhibitor,O
of,O
CYP2C8,O
.,O
When,O
co,O
‐,O
administered,O
with,O
ATV,O
.,O
increased,O
serum,O
levels,O
of,O
psychotropics,O
that,O
are,O
substrates,O
of,O
CYP3A4,O
can,O
occur,O
.,O
This,O
is,O
especially,O
true,O
for,O
lurasidone,O
.,O
que,O
‐,O
tiapine,O
and,O
ziprasidone,O
.,O
Their,O
levels,O
can,O
be,O
raised,O
significant,O
‐,O
ly,O
.,O
thus,O
increasing,O
the,O
risk,O
of,O
serious,O
adverse,O
effects,O
.,O
includ,O
‐,O
ing,O
prolongation,O
of,O
QTc,O
interval,O
.,O
These,O
combinations,O
should,O
be,O
avoided,O
if,O
possible,O
.,O
Other,O
CYP3A4,O
substrates,O
.,O
such,O
aripiprazole,O
.,O
clozapine,O
.,O
haloperidol,O
.,O
iloperidone,O
.,O
risperidone,O
and,O
zuclopen,O
‐,O
tixol,O
.,O
as,O
well,O
as,O
some,O
benzodiazepines,O
(,O
e.g.,O
clonazepam,O
.,O
diazepam,O
and,O
midazolam,O
),O
and,O
certain,O
antidepressants,O
(,O
e.g.,O
citalopram,O
.,O
es,O
‐,O
citalopram,O
.,O
clomipramine,O
.,O
imipramine,O
and,O
mirtazapine,O
.,O
amongst,O
others,O
),O
can,O
also,O
be,O
affected,O
in,O
the,O
same,O
way,O
when,O
co,O
‐,O
administered,O
with,O
ATV,O
and,O
may,O
require,O
dose,O
adjustments,O
or,O
monitoring,O
.,O
Carba,O
‐,O
mazepine,O
and,O
ATV,O
together,O
can,O
lead,O
to,O
increased,O
levels,O
of,O
carba,O
‐,O
mazepine,O
and,O
reduced,O
levels,O
of,O
ATV,O
and,O
this,O
combination,O
with,O
drugs,CRIMINAL_CHARGE
highly,O
dependent,O
on,O
CYP2C8,O
with,O
narrow,O
therapeutic,O
indices,O
is,O
not,O
recommended,O
(,O
no,O
psychotropic,O
meets,O
this,O
definition,O
),O
.,O
For,O
each,O
drug,O
identified,O
.,O
trial,O
outcome,O
data,O
.,O
dosing,O
regimens,O
.,O
ad,O
‐,O
verse,O
effects,O
and,O
drug,O
interaction,O
potential,O
are,O
reported,O
in,O
the,O
following,O
.,O
For,O
specific,O
drug,O
Dose,O
‐,O
related,O
asymptomatic,O
prolonga,O
‐,O
tions,O
in,O
the,O
PR,STATE_OR_PROVINCE
interval,O
with,O
ATV,O
have,O
been,O
observed,O
in,O
clinical,O
studies,O
.,O
Caution,O
should,O
be,O
used,O
when,O
prescribing,O
ATV,O
with,O
medici,O
‐,O
nal,O
products,O
that,O
have,O
the,O
potential,O
to,O
increase,O
the,O
QT,O
interval,O
;,O
a,O
potential,O
effect,O
of,O
many,O
antipsychotic,O
drugs,CRIMINAL_CHARGE
and,O
some,O
antide,O
‐,O
pressants,O
.,O
and,O
/,O
or,O
in,O
patients,O
with,O
pre,O
‐,O
existing,O
risk,O
factors,O
(,O
bradycardia,O
.,O
long,O
congenital,O
QT,O
.,O
electrolyte,O
imbalances,O
accord,O
‐,O
ing,O
to,O
the,O
Liverpool,ORGANIZATION
An,O
antiretroviral,O
medication,O
used,O
to,O
treat,O
and,O
prevent,O
the,O
human,O
immunodeficiency,O
virus,O
(,O
HIV,CAUSE_OF_DEATH
),O
AZI,O
is,O
a,O
macrolide,O
antibiotic,O
used,O
in,O
combination,O
with,O
HCLQ,O
(,O
for,O
dosage,O
information,O
see,O
HCLQ,O
),O
.,O
Dosage,O
information,O
.,O
Some,O
reports,O
have,O
emerged,O
where,O
the,O
following,O
regimen,O
was,O
used,O
for,O
COVID,O
‐,O
19,NUMBER
pneumo,O
‐,O
nia,O
:,O
ATV,O
400,NUMBER
mg,O
daily,SET
for,O
2,DURATION
weeks,DURATION
in,O
combination,O
with,O
oseltamivir,O
150,NUMBER
mg,O
twice,O
daily,SET
+,O
/,O
methylprednisolone,O
40,NUMBER
mg,O
twice,O
data,O
for,O
its,O
use,O
to,O
support,O
this,O
.,O
Adverse,O
effects,O
.,O
Adverse,O
effects,O
include,O
gastrointestinal,O
effects,O
.,O
arrhythmias,O
.,O
QT,O
prolongation,O
and,O
hepat,O
‐,O
ic,O
disorders,O
.,O
Drug,O
interactions,O
.,O
AZI,O
does,O
not,O
interact,O
signifi,O
‐,O
cantly,O
with,O
the,O
hepatic,O
cytochrome,O
P450,O
system,O
.,O
It,O
is,O
not,O
be,O
‐,O
lieved,O
to,O
undergo,O
pharmacokinetic,O
D,O
Bishara,PERSON
.,O
C,O
Kalafatis,PERSON
et,O
al,O
.,O
Mood,O
stabilisers,O
Therapeutic,O
Advances,O
in,O
Psychopharmacology,O
10,NUMBER
Text,O
Legend,O
Potential,O
increase,O
exposure,O
of,O
drug,O
specified,O
Poten,O
‐,O
tial,O
decrease,O
exposure,O
of,O
drug,O
specified,O
No,O
significant,O
effect,O
on,O
drug,O
serum,O
levels,O
One,NUMBER
or,O
both,O
drugs,CRIMINAL_CHARGE
may,O
cause,O
QT,O
and,O
/,O
or,O
PR,STATE_OR_PROVINCE
pro,O
‐,O
longation,O
.,O
ECG,O
monitoring,O
advised,O
One,NUMBER
or,O
both,O
drugs,CRIMINAL_CHARGE
may,O
cause,O
bone,O
marrow,O
suppression,O
.,O
Monitor,O
FBC,O
One,NUMBER
or,O
more,O
drugs,CRIMINAL_CHARGE
may,O
reduce,O
seizure,O
threshold,O
.,O
Monitor,O
closely,O
.,O
Theoretical,O
drug,O
interaction,O
based,O
on,O
CYP,O
metabolism,O
.,O
however,O
no,O
specific,O
reports,O
These,O
drugs,CRIMINAL_CHARGE
should,O
not,O
be,O
co,O
‐,O
administered,O
Potential,O
interaction,O
which,O
may,O
re,O
‐,O
quire,O
a,O
dose,O
adjustment,O
or,O
close,O
monitoring,O
Potential,O
interaction,O
likely,O
to,O
be,O
of,O
weak,O
intensity,O
.,O
Additional,O
action,O
/,O
monitoring,O
or,O
dosage,O
adjustment,O
unlikely,O
to,O
be,O
required,O
No,O
clinically,O
signifi,O
‐,O
cant,O
interaction,O
expected,O
ATV,O
.,O
atazanavir,O
;,O
AZI,O
.,O
azithromycin,O
;,O
CLQ,O
.,O
chloroquine,O
;,O
CYP,O
.,O
cytochrome,O
P450,O
;,O
DIP,O
.,O
dipyridamole,O
;,O
ECG,O
.,O
electrocardiogram,O
;,O
FAM,O
.,O
famotidine,O
;,O
FAVI,O
.,O
favipiravir,O
;,O
FBC,O
.,O
full,O
blood,O
count,TITLE
;,O
HCLQ,O
.,O
hydroxychloroquine,O
;,O
LPV,O
/,O
r,O
.,O
lopinavir,O
/,O
riton,O
‐,O
avir,O
;,O
NITAZ,LOCATION
.,O
nitazoxanide,O
;,O
RDV,O
.,O
remdesivir,O
;,O
RBV,O
.,O
ribavirin,O
;,O
TCZ,O
.,O
tocilizumab,O
.,O
Dementia,CAUSE_OF_DEATH
drugs,CRIMINAL_CHARGE
D,PERSON
Bishara,PERSON
.,O
C,O
Kalafatis,PERSON
et,O
al,O
.,O
Ther,O
‐,O
apeutic,O
Advances,O
in,O
Psychopharmacology,O
10,NUMBER
drug,O
interactions,O
.,O
He,O
‐,O
patic,O
cytochrome,O
P450,O
induction,O
or,O
inactivation,O
via,O
cy,O
‐,O
tochromemetabolite,O
complex,O
does,O
not,O
occur,O
with,O
AZI,O
.,O
AZI,O
is,O
known,O
to,O
be,O
a,O
P,O
‐,O
glycoprotein,O
(,O
P,O
‐,O
gp,O
),O
inhibitor,O
and,O
.,O
if,O
co,O
‐,O
administered,O
with,O
P,O
‐,O
gp,O
substrates,O
(,O
e.g.,O
digoxin,O
.,O
colchicine,O
),O
.,O
it,O
has,O
been,O
re,O
‐,O
ported,O
to,O
result,O
in,O
increased,O
serum,O
levels,O
.,O
requiring,O
monitor,O
‐,O
ing,O
.10,NUMBER
Psychotropics,O
are,O
not,O
known,O
to,O
be,O
P,O
‐,O
gp,O
substrates,O
.,O
Whilst,O
pharmacokinetic,O
drug,O
interactions,O
are,O
not,O
a,O
problem,O
with,O
AZI,O
.,O
it,O
is,O
important,O
to,O
note,O
that,O
serious,O
pharmacodynamic,O
drug,O
interac,O
‐,O
tions,O
do,O
exist,O
when,O
co,O
‐,O
administered,O
with,O
psychotropic,O
agents,O
.,O
Since,O
QTc,O
prolongation,O
can,O
be,O
an,O
effect,O
exercised,O
when,O
used,O
to,O
‐,O
gether,O
as,O
the,O
risk,O
for,O
QTc,O
prolongation,O
is,O
further,O
increased,O
.,O
In,O
addition,O
.,O
some,O
psychotropics,O
are,O
known,O
to,O
cause,O
neutropenia,O
or,O
agranulocytosis,O
(,O
particularly,O
clozapine,O
and,O
carbamazepine,O
),O
.,O
which,O
is,O
also,O
a,O
potential,O
adverse,O
effect,O
of,O
AZI,O
.,O
Chloroquine,O
and,O
hy,O
‐,O
droxychloroquine,O
CLQ,O
and,O
HCLQ,ORGANIZATION
are,O
oral,O
drugs,CRIMINAL_CHARGE
that,O
have,O
been,O
used,O
for,O
the,O
prophylaxis,O
and,O
treatment,O
of,O
malaria,CAUSE_OF_DEATH
.,O
and,O
the,O
treatment,O
of,O
certain,O
inflammatory,O
conditions,O
such,O
as,O
rheumatoid,O
arthritis,O
and,O
systemic,O
lupus,CAUSE_OF_DEATH
erythematosus,CAUSE_OF_DEATH
.,O
Both,O
drugs,CRIMINAL_CHARGE
are,O
currently,DATE
being,O
trialled,O
in,O
patients,O
with,O
mild,O
‐,O
to,O
‐,O
severe,O
COVID,O
‐,O
19.2,NUMBER
HCQL,O
is,O
also,O
being,O
trialled,O
for,O
post,O
‐,O
exposure,O
prophylaxis,O
to,O
prevent,O
progres,O
‐,O
sion,O
to,O
symptomatic,O
disease,CAUSE_OF_DEATH
after,O
known,O
exposure,O
.,O
CLQ,O
is,O
being,O
trialled,O
for,O
prevention,O
of,O
COVID19,O
in,O
the,O
healthcare,O
setting,O
.11,NUMBER
Chloroquine,O
.,O
Use,O
of,O
CLQ,O
is,O
included,O
in,O
treatment,O
guidelines,O
from,O
Chinas,ORGANIZATION
National,ORGANIZATION
Health,ORGANIZATION
Commission,ORGANIZATION
and,O
was,O
reportedly,O
associated,O
with,O
reduced,O
progression,O
of,O
disease,CAUSE_OF_DEATH
and,O
decreased,O
China,COUNTRY
recom,O
‐,O
mends,O
CLQ,O
in,O
mild,O
to,O
severe,O
cases,O
of,O
COVID,O
‐,O
19,NUMBER
as,O
it,O
may,O
improve,O
the,O
success,O
rate,O
of,O
treatment,O
.,O
shorten,O
hospital,O
stay,O
and,O
improve,O
patient,O
outcome,O
.12,NUMBER
Dosing,O
information,O
.,O
According,O
to,O
a,O
consensus,O
statement,O
from,O
a,O
multicentre,O
collaboration,O
group,O
diagnosed,O
as,O
having,O
mild,O
.,O
moderate,O
or,O
severe,O
cases,O
of,O
novel,O
coronavirus,O
pneu,O
‐,O
monia,O
and,O
without,O
contraindications,O
to,O
CLQ,O
.12,NUMBER
Hydroxychloroquine,O
.,O
There,O
is,O
a,O
considerable,O
interest,O
for,O
the,O
use,O
of,O
HCLQ,O
to,O
treat,O
COVID,O
‐,O
19,NUMBER
disease,CAUSE_OF_DEATH
;,O
however,O
.,O
significant,O
methodological,O
limitations,O
do,O
not,O
allow,O
for,O
definitive,O
conclusions,O
.,O
A,O
small,O
randomised,O
con,O
‐,O
trolled,O
trial,O
(,O
20,NUMBER
patients,O
),O
found,O
that,O
HCLQ,O
(,O
with,O
or,O
without,O
AZI,O
),O
was,O
efficient,O
in,O
reducing,O
viral,O
nasopharyngeal,O
carriage,O
of,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
in,O
36,DURATION
days,DURATION
in,O
most,O
patients,O
.,O
The,O
addition,O
of,O
AZI,O
(,O
to,O
six,NUMBER
patients,O
),O
was,O
thought,O
to,O
be,O
synergistic,O
and,O
the,O
combination,O
was,O
found,O
to,O
be,O
significantly,O
more,O
efficient,O
for,O
virus,O
elimination13,O
;,O
however,O
the,O
sample,O
was,O
small,O
.,O
the,O
majority,O
of,O
patients,O
presented,O
with,O
mild,O
symptoms,O
and,O
the,O
suffered,O
from,O
other,O
significant,O
co,O
‐,O
morbidities,O
.,O
A,O
similar,O
combination,O
trial,O
of,O
HCLQ,O
and,O
AZI,O
in,O
11,NUMBER
participants,O
did,O
not,O
replicate,O
the,O
previously,DATE
mentioned,O
results,O
.,O
Crucially,O
.,O
8,NUMBER
out,O
of,O
11,NUMBER
had,O
significant,O
comorbidities,O
associated,O
with,O
poor,O
outcomes,O
.14,NUMBER
Another,O
randomised,O
open,O
‐,O
label,O
study,O
in,O
30,NUMBER
Chinese,NATIONALITY
participants,O
(,O
1:1,NUMBER
randomisation,O
),O
did,O
not,O
offer,O
conclusive,O
results,O
on,O
the,O
efficacy,O
of,O
HCLQ,O
.15,NUMBER
The,O
only,O
publicly,O
available,O
randomised,O
control,O
trial,O
of,O
HCLQ,O
in,O
62,NUMBER
Chinese,NATIONALITY
participants,O
re,O
‐,O
mains,O
HCLQ,O
/,O
AZI,O
combination,O
is,O
associated,O
with,O
high,O
risk,O
of,O
QTc,O
prolongation,O
.,O
In,O
84,NUMBER
adult,O
patients,O
with,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
infection,CAUSE_OF_DEATH
treated,O
with,O
this,O
combination,O
.,O
QTc,O
was,O
significantly,O
prolonged,O
from,O
baseline,O
between,O
days,DURATION
3,NUMBER
and,O
4,NUMBER
.,O
In,O
30,PERCENT
%,PERCENT
of,O
patients,O
QTc,O
in,O
‐,O
creased,O
by,O
greater,O
than,O
40,NUMBER
ms.,O
In,O
11,PERCENT
%,PERCENT
of,O
patients,O
QTc,O
increased,O
to,O
>,O
500,NUMBER
ms,O
.,O
representing,O
a,O
high,O
risk,O
group,O
for,O
arrhythmia,O
.,O
The,O
development,O
of,O
acute,O
renal,CAUSE_OF_DEATH
failure,CAUSE_OF_DEATH
but,O
not,O
baseline,O
QTc,O
was,O
a,O
strong,O
predictor,O
of,O
extreme,O
QTc,O
prolongation,O
.17,NUMBER
Dosing,O
informa,O
‐,O
tion,O
.,O
HCLQ,O
200,NUMBER
mg,O
three,NUMBER
times,O
a,DURATION
day,DURATION
for,O
10,DURATION
days,DURATION
.,O
(,O
Recent,O
studies,O
linking,O
HCLQ,O
treatment,O
to,O
viral,O
load,O
reduction,O
in,O
COVID,O
‐,O
19,NUMBER
pa,O
‐,O
tients,O
did,O
so,O
with,O
higher,O
dose,O
treatment,O
.,O
using,O
either,O
a,O
600,NUMBER
mg,O
daily,SET
dose,O
or,O
1000,DATE
mg,O
daily,SET
dose,O
),O
.18,NUMBER
AZI,O
dosage,O
used,O
was,O
(,O
500,NUMBER
mg,O
daily,SET
day,DURATION
1,NUMBER
followed,O
by,O
250,NUMBER
mg,O
per,O
day,DURATION
.,O
the,DURATION
next,DURATION
4,DURATION
days,DURATION
),O
.,O
It,O
has,O
been,O
suggested,O
that,O
early,O
treatment,O
is,O
important,O
.3,NUMBER
D,O
Bishara,PERSON
.,O
C,O
Kalafatis,PERSON
et,O
al,O
.,O
Adverse,O
effects,O
for,O
CLQ,O
/,O
HCLQ,O
.,O
Gastrointestinal,O
effects,O
.,O
such,O
as,O
vomiting,O
and,O
diarrhoea,CAUSE_OF_DEATH
.,O
are,O
the,O
most,O
common,O
ad,O
‐,O
verse,O
effects,O
of,O
these,O
two,NUMBER
drugs,CRIMINAL_CHARGE
.,O
Patients,O
with,O
long,O
‐,O
term,O
expo,O
‐,O
sure,O
to,O
CLQ,O
suffer,O
from,O
severe,O
side,O
effects,O
such,O
as,O
retinopathy,O
and,O
cardiotoxic,O
effects,O
.19,NUMBER
CLQ,O
and,O
HCLQ,O
have,O
been,O
shown,O
to,O
pro,O
‐,O
long,O
the,O
QTc,O
interval,O
in,O
some,O
patients,O
and,O
should,O
therefore,O
be,O
used,O
with,O
caution,O
in,O
patients,O
receiving,O
concomitant,O
drugs,CRIMINAL_CHARGE
known,O
to,O
prolong,O
the,O
QT,O
interval,O
or,O
where,O
a,O
drug,O
interaction,O
may,O
in,O
‐,O
crease,O
CLQ,O
or,O
HCLQ,O
exposure,O
(,O
see,O
drug,O
interactions,O
in,O
the,O
follow,O
‐,O
ing,O
),O
.,O
Electrocardiogram,O
(,O
ECG,O
),O
monitoring,O
would,O
be,O
recommended,O
in,O
these,O
instances,O
.9,NUMBER
Caution,O
is,O
also,O
advised,O
when,O
considering,O
these,O
drugs,CRIMINAL_CHARGE
in,O
patients,O
with,O
chronic,O
medical,O
conditions,O
(,O
e.g.,O
renal,O
failure,O
.,O
hepatic,O
disease,CAUSE_OF_DEATH
),O
.,O
HCLQ,ORGANIZATION
has,O
similar,O
therapeutic,O
effects,O
to,O
CLQ,O
.,O
but,O
less,O
severe,O
adverse,O
effects,O
.,O
It,O
is,O
considered,O
safe,O
in,O
pregnancy,O
and,O
is,O
more,O
readily,O
available,O
in,O
some,O
countries,O
.,O
More,O
importantly,O
.,O
the,O
maximum,O
dose,O
for,O
HCLQ,O
is,O
1200,NUMBER
mg,O
.,O
which,O
has,O
an,O
antiviral,O
effect,O
equivalent,O
to,O
750,NUMBER
mg,O
CLQ,O
(,O
for,O
which,O
the,O
maximum,O
tolerable,O
dose,O
can,O
be,O
500,NUMBER
mg,O
),O
.,O
Hence,O
.,O
HCLQ,O
can,O
be,O
administered,O
at,O
a,O
higher,O
equivalent,O
dosage,O
and,O
may,O
therefore,O
achieve,O
more,O
pow,O
‐,O
erful,O
antiviral,O
effect,O
.20,NUMBER
The,O
United,COUNTRY
States,COUNTRY
Food,O
and,O
Drug,O
Admin,O
‐,O
istration,O
(,O
FDA,ORGANIZATION
),O
has,O
recently,DATE
issued,O
a,O
warning,O
that,O
CLQ,O
and,O
HCLQ,O
should,O
be,O
used,O
for,O
COVID,O
‐,O
19,NUMBER
only,O
when,O
patients,O
can,O
be,O
appropri,O
‐,O
ately,O
monitored,O
in,O
the,O
hospital,O
setting,O
or,O
are,O
enrolled,O
in,O
a,O
clinical,O
trial,O
with,O
appropriate,O
screening,O
and,O
monitoring,O
.,O
use,O
for,O
COVID,O
‐,O
19,NUMBER
outside,O
the,O
hospital,O
setting,O
after,O
reports,O
of,O
QT,O
in,O
‐,O
terval,O
prolongation,O
and,O
ventricular,O
tachycardia,O
.21,NUMBER
Drug,O
interac,O
‐,O
tions,O
.,O
CLQ,O
and,O
HCLQ,O
undergo,O
CYP,O
‐,O
mediated,O
metabolism,O
by,O
CYPs,O
2C8,O
.,O
3A4,O
and,O
2D6,O
.,O
Co,O
‐,O
administration,O
with,O
inhibitors,O
and,O
inducers,O
of,O
these,O
isoenzymes,O
may,O
increase,O
or,O
decrease,O
exposure,O
to,O
them,O
.,O
re,O
‐,O
spectively,O
.,O
and,O
dose,O
changes,O
or,O
additional,O
monitoring,O
could,O
be,O
considered,O
.,O
Fluoxetine,O
and,O
paroxetine,O
are,O
inhibitors,O
of,O
both,O
CYP3A4,O
and,O
CYP2D6,O
and,O
can,O
therefore,O
lead,O
to,O
increased,O
levels,O
of,O
CLQ,O
and,O
HCLQ,O
.,O
in,O
turn,O
increasing,O
the,O
risk,O
of,O
QTc,O
prolongation,O
.,O
Other,O
psychotropics,O
that,O
are,O
important,O
inhibitors,O
of,O
CYP2D6,O
in,O
‐,O
clude,O
amitriptyline,O
.,O
bupropion,O
and,O
duloxetine,O
.,O
Carbamazepine,O
in,O
‐,O
duces,O
CYP3A4,O
and,O
can,O
lead,O
to,O
reduced,O
levels,O
of,O
CLQ,O
and,O
HCLQ,O
.,O
CLQ,O
and,O
HCLQ,O
are,O
moderate,O
inhibitors,O
of,O
CYP2D6,O
and,O
P,O
‐,O
gp,O
.,O
and,O
caution,O
may,O
be,O
required,O
when,O
co,O
‐,O
administering,O
medication,O
with,O
a,O
narrow,O
therapeutic,O
index,O
that,O
are,O
metabolised,O
or,O
transported,O
by,O
these,O
pathways,O
.9,NUMBER
Psychotropics,O
that,O
are,O
substrates,O
of,O
CYP2D6,O
and,O
that,O
will,O
undergo,O
reduced,O
metabolism,O
and,O
have,O
increased,O
levels,O
when,O
co,O
‐,O
administered,O
with,O
these,O
drugs,CRIMINAL_CHARGE
include,O
aripiprazole,O
.,O
chlorpro,O
‐,O
mazine,O
.,O
iloperidone,O
.,O
olanzapine,O
.,O
risperidone,O
.,O
zuclopentixol,O
.,O
clomipramine,O
.,O
The,O
following,O
pharmacodynamic,O
drug,O
interactions,O
should,O
be,O
considered,O
carefully,O
.,O
Since,O
CLQ,O
and,O
HCLQ,O
have,O
been,O
shown,O
to,O
prolong,O
QTc,O
interval,O
.,O
caution,O
should,O
be,O
used,O
when,O
co,O
‐,O
ad,O
‐,O
ministered,O
with,O
most,O
antipsychotics,O
and,O
some,O
antidepressant,O
drugs,CRIMINAL_CHARGE
.,O
such,O
as,O
tricyclic,O
antidepressants,O
.,O
c,O
italopram,O
.,O
escitalo,O
‐,O
pram,O
.,O
venlafaxine,O
.,O
trazodone,O
and,O
lithium,O
addition,O
.,O
CLQ,O
and,O
HCLQ,O
have,O
been,O
reported,O
to,O
cause,O
bone,O
marrow,O
failure,O
.,O
neutropenia,O
and,O
agranulocytosis,O
Therefore,O
.,O
co,O
‐,O
administration,O
with,O
carbamazepine,O
should,O
be,O
avoided,O
.,O
and,O
if,O
used,O
with,O
clozapine,O
.,O
cautious,O
use,O
and,O
close,O
monitoring,O
are,O
advised,O
.,O
Furthermore,O
.,O
CLQ,O
and,O
HCLQ,O
may,O
lower,O
the,O
convulsive,O
threshold,O
and,O
thus,O
antagonise,O
the,O
actions,O
of,O
antiepileptics,O
such,O
as,O
c,O
arbamazepine,O
.,O
lamotrigine,O
or,O
sodium,O
val,O
‐,O
proate,O
.,O
They,O
should,O
also,O
be,O
used,O
with,O
caution,O
with,O
bupropion,O
.,O
which,O
can,O
also,O
reduce,O
seizure,O
threshold,O
.,O
Dipyridamole,O
(,O
DIP,O
),O
is,O
an,O
antiplatelet,O
agent,O
and,O
acts,O
as,O
a,O
phosphodiesterase,O
(,O
PDE,O
),O
in,O
‐,O
hibitor,O
that,O
increases,O
intracellular,O
cAMP,O
/,O
cGMP,O
.,O
Apart,O
from,O
the,O
well,O
‐,O
known,O
antiplatelet,O
function,O
.,O
DIP,O
may,O
provide,O
potential,O
ther,O
‐,O
apeutic,O
benefits,O
to,O
patients,O
clinical,O
trials,O
conducted,O
in,O
China,COUNTRY
.,O
have,O
demonstrated,O
that,O
it,O
has,O
a,O
broad,O
spectrum,O
antiviral,O
activi,O
‐,O
ty,O
.,O
particularly,O
efficacious,O
against,O
positivestranded,O
RNA,O
virus,O
‐,O
es,O
;,O
it,O
suppresses,O
inflammation,O
and,O
promotes,O
mucosal,O
healing,O
.,O
and,O
.,O
as,O
a,O
pan,O
‐,O
PDE,O
inhibitor,O
.,O
it,O
may,O
also,O
prevent,O
acute,O
injury,O
and,O
pro,O
‐,O
gressive,O
fibrosis,O
of,O
the,O
lung,O
.,O
heart,O
.,O
liver,O
and,O
kidneys,O
.22,NUMBER
COVID,O
‐,O
19,NUMBER
infection,CAUSE_OF_DEATH
can,O
cause,O
acute,O
respiratory,O
distress,O
syndrome,O
.,O
hypercoagulability,O
.,O
hypertension,CAUSE_OF_DEATH
and,O
multiorgan,O
dysfunction,O
.,O
In,O
an,O
analysis,O
of,O
a,O
randomly,O
collected,O
cohort,O
of,O
124,NUMBER
patients,O
with,O
the,O
disease,CAUSE_OF_DEATH
.,O
researchers,O
from,O
China,COUNTRY
found,O
that,O
hypercoagulability,O
as,O
Therapeutic,O
Advances,O
in,O
Psychopharmacology,O
10,NUMBER
indicated,O
by,O
el,O
‐,O
evated,O
concentrations,O
of,O
D,O
‐,O
dimers,O
was,O
associated,O
with,O
disease,CAUSE_OF_DEATH
severity,O
.,O
They,O
identified,O
DIP,O
.,O
which,O
suppressed,O
COVID,O
‐,O
19,NUMBER
replica,O
‐,O
tion,O
in,O
vitro,O
.,O
22,NUMBER
Dosage,O
information,O
.,O
The,O
daily,SET
treatment,O
proto,O
‐,O
col,O
comprises,O
oral,O
DIP,O
150,NUMBER
mg,O
in,O
three,NUMBER
separate,O
doses,O
for,O
14,NUMBER
con,O
‐,O
secutive,O
days,DURATION
.,O
Adverse,O
effects,O
.,O
Gastrointestinal,O
adverse,O
effects,O
are,O
common,O
with,O
DIP,O
.,O
and,O
thrombocytopenia,O
and,O
tachycardia,O
have,O
been,O
reported,O
although,O
frequency,O
is,O
not,O
known,O
.23,NUMBER
Because,O
DIP,O
is,O
a,O
PDE,O
inhibitor,O
and,O
can,O
exacerbate,O
bronchospasm,O
(,O
frequency,O
not,O
known,O
),O
.,O
particularly,O
in,O
patients,O
with,O
reactive,O
airway,O
disease,CAUSE_OF_DEATH
and,O
/,O
or,O
chronic,CAUSE_OF_DEATH
obstructive,CAUSE_OF_DEATH
pulmonary,CAUSE_OF_DEATH
disease,CAUSE_OF_DEATH
(,O
COPD,O
),O
.,O
Therapy,O
with,O
DIP,O
is,O
contraindicated,O
in,O
patients,O
with,O
active,O
wheezing,O
and,O
should,O
be,O
administered,O
cautiously,O
in,O
patients,O
with,O
asthma,CAUSE_OF_DEATH
or,O
COPD,O
and,O
therefore,O
in,O
COVID19,O
patients,O
as,O
well,O
.24,NUMBER
Drug,O
interactions,O
.,O
Metabolism,O
of,O
DIP,O
occurs,O
in,O
the,O
liver,O
.,O
DIP,O
is,O
metabolized,O
by,O
con,O
‐,O
jugation,O
with,O
glucuronic,O
acid,O
to,O
form,O
mainly,O
a,O
monoglucuronide,O
and,O
only,O
small,O
amounts,O
of,O
diglucuronide,O
.,O
In,O
plasma,O
.,O
about,O
80,PERCENT
%,PERCENT
of,O
the,O
total,O
amount,O
is,O
parent,O
compound,O
.,O
20,PERCENT
%,PERCENT
of,O
the,O
total,O
amount,O
is,O
monoglucuronide,O
with,O
oral,O
administration,O
.23,NUMBER
The,O
bleeding,O
risk,O
as,O
‐,O
sociated,O
with,O
DIP,O
might,O
be,O
further,O
increased,O
by,O
the,O
concurrent,O
use,O
of,O
a,O
serotonin,O
reuptake,O
inhibitors,O
(,O
SRIs,O
),O
.,O
Serotonin,O
release,O
by,O
platelets,O
plays,O
an,O
important,O
role,O
in,O
have,O
documented,O
the,O
oc,O
‐,O
currence,O
of,O
bleeding,O
episodes,O
in,O
patients,O
treated,O
with,O
psy,O
‐,O
chotropic,O
agents,O
that,O
interfere,O
with,O
serotonin,O
reuptake,O
.,O
Bleeding,O
events,O
related,O
to,O
SRIs,O
have,O
ranged,O
from,O
ecchymosis,O
.,O
haematoma,O
.,O
epistaxis,O
and,O
petechiae,O
to,O
life,O
‐,O
threatening,O
haemorrhages,O
.25,NUMBER
Therefore,O
.,O
caution,O
should,O
be,O
used,O
with,O
citalopram,O
.,O
escitalopram,O
.,O
fluoxetine,O
.,O
paroxetine,O
and,O
sertraline,O
as,O
well,O
as,O
clomipramine,O
.,O
duloxetine,O
.,O
venlafaxine,O
and,O
vortioxetine,O
.,O
Monitor,O
closely,O
for,O
bleeding,O
.,O
Gastroprotection,O
(,O
such,O
as,O
a,O
proton,O
pump,O
inhibitor,O
),O
in,O
those,O
at,O
high,O
risk,O
of,O
gastrointestinal,O
bleeding,O
(,O
e.g.,O
history,O
of,O
gastrointestinal,O
bleeding,O
.,O
the,O
elderly,O
),O
should,O
be,O
considered,O
.4,NUMBER
DIP,O
may,O
also,O
increase,O
the,O
hypotensive,O
effect,O
of,O
psychotropic,O
drugs,CRIMINAL_CHARGE
that,O
reduce,O
blood,O
pressure,O
and,O
may,O
counteract,O
the,O
anti,O
‐,O
cholinesterase,O
effect,O
of,O
cholinesterase,O
inhibitors,O
.23.26,NUMBER
Famoti,O
‐,O
dine,O
(,O
FAM,O
),O
is,O
a,O
H2,O
antagonist,O
use,O
to,O
treat,O
heartburn,O
.,O
ulcers,O
and,O
ZollingerEllison,O
syndrome,O
.,O
Earlier,O
in,O
the,O
outbreak,O
.,O
doctors,O
who,O
worked,O
with,O
coronavirus,O
patients,O
in,O
Wuhan,CITY
.,O
China,COUNTRY
discovered,O
that,O
.,O
although,O
one,NUMBER
in,O
five,NUMBER
COVID,O
‐,DATE
19,DATE
patients,O
over,O
the,O
age,O
of,O
80,NUMBER
died,O
.,O
many,O
of,O
those,O
who,O
survived,O
had,O
been,O
taking,O
the,O
heartburn,O
medica,O
‐,O
tion,O
FAM,O
.,O
In,O
fact,O
.,O
hospitalized,O
COVID,O
‐,O
19,NUMBER
patients,O
on,O
FAM,O
appeared,O
to,O
be,O
dying,O
at,O
a,O
rate,O
of,O
about,O
14,PERCENT
%,PERCENT
compared,O
with,O
27,PERCENT
%,PERCENT
for,O
those,O
not,O
on,O
the,O
drug,O
.,O
and,O
.,O
although,O
the,O
analysis,O
was,O
crude,O
.,O
the,O
result,O
was,O
not,O
statistically,O
significant,O
and,O
studies,O
on,O
the,O
Chinese,NATIONALITY
pa,O
‐,O
tients,O
have,O
to,O
encourage,O
US,COUNTRY
scientists,O
to,O
explore,O
FAMs,O
As,O
part,O
of,O
a,O
clinical,O
trial,O
.,O
patients,O
at,O
New,STATE_OR_PROVINCE
York,STATE_OR_PROVINCE
Citys,LOCATION
Northwell,LOCATION
Health,LOCATION
have,O
been,O
receiving,O
FAM,O
intravenously,O
.,O
at,O
a,O
dose,O
nine,NUMBER
times,O
greater,O
than,O
what,O
people,O
typically,O
take,O
for,O
heartburn,O
(,O
specific,O
dosing,O
details,O
are,O
not,O
available,O
),O
.,O
The,O
randomised,O
.,O
double,O
‐,O
blind,O
trial,O
.,O
which,O
began,O
on,O
7,DATE
April,DATE
2020,DATE
.,O
has,O
enrolled,O
187,NUMBER
participants,O
to,O
date,O
.,O
but,O
expects,O
to,O
expand,O
to,O
a,O
total,O
of,O
1174,DATE
individuals,O
in,O
critical,O
status,O
.,O
including,O
many,O
on,O
Adverse,MISC
effects,O
.,O
ECG,O
changes,O
are,O
seen,O
;,O
prolonged,O
QT,O
interval,O
has,O
been,O
reported,O
in,O
patients,O
with,O
moderate,O
‐,O
to,O
‐,O
severe,O
renal,O
impairment,O
.,O
The,O
FDA,ORGANIZATION
has,O
received,O
reports,O
of,O
torsades,O
de,O
pointes,O
occurring,O
with,O
FAM,O
.,O
There,O
have,O
al,O
‐,O
so,O
been,O
rare,O
reports,O
of,O
seizures,O
.,O
thrombocytopenia,O
.,O
leukopenia,O
.,O
agranulocytosis,O
.,O
pancytopenia,O
intrahepatic,O
cholestasis,O
.,O
jaundice,CAUSE_OF_DEATH
and,O
increased,O
liver,O
enzyme,O
abnormalities,O
.,O
In,O
addition,O
.,O
it,O
can,O
very,O
rarely,O
cause,O
psychiatric,O
effects,O
such,O
as,O
depression,O
.,O
anxiety,O
and,O
Drug,O
interactions,O
.,O
FAM,O
is,O
considered,O
a,O
weak,O
CYP1A2,O
inhibitor,O
and,O
may,O
lead,O
to,O
substantial,O
increases,O
in,O
blood,O
concentrations,O
of,O
CYP1A2,O
substrates,O
.,O
Whilst,O
there,O
are,O
no,O
reports,O
.,O
theoretically,O
.,O
co,O
‐,O
administration,O
can,O
lead,O
to,O
increased,O
levels,O
of,O
clozapine,O
.,O
olanzapine,O
and,O
agomelatine,O
as,O
they,O
are,O
predominantly,O
CYP,O
1A2,O
sub,O
‐,O
strates,O
.29,NUMBER
FAM,O
may,O
cause,O
QTc,O
prolongation,O
.,O
Theoretically,O
.,O
coad,O
‐,O
ministration,O
with,O
other,O
agents,O
that,O
can,O
prolong,O
the,O
QT,O
interval,O
may,O
result,O
in,O
additive,O
effects,O
and,O
increased,O
risk,O
of,O
ventricular,O
arrhythmias,O
including,O
torsade,O
de,O
pointes,O
and,O
sudden,O
death,O
.,O
Ac,O
‐,O
cording,O
to,O
the,O
manufacturer,TITLE
.,O
prolongation,O
of,O
D,O
Bishara,PERSON
.,O
C,O
Kalafatis,PERSON
et,O
al,O
.,O
the,O
QT,O
interval,O
has,O
been,O
reported,O
very,O
rarely,O
in,O
patients,O
with,O
impaired,O
renal,O
function,O
whose,O
dose,O
/,O
dosing,O
in,O
‐,O
terval,O
of,O
FAM,O
may,O
not,O
have,O
been,O
adjusted,O
appropriately,O
.,O
In,O
gener,O
‐,O
al,O
.,O
the,O
risk,O
of,O
an,O
individual,O
agent,O
.,O
or,O
a,O
combination,O
of,O
these,O
agents,O
.,O
causing,O
ventricular,O
arrhythmia,O
in,O
association,O
with,O
be,O
in,O
‐,O
creased,O
by,O
certain,O
underlying,O
risk,O
factors,O
such,O
as,O
congenital,O
long,O
QT,O
syndrome,O
.,O
cardiac,O
disease,CAUSE_OF_DEATH
and,O
electrolyte,O
disturbances,O
(,O
e.g.,O
hypokalemia,O
.,O
hypomagnesemia,O
),O
.,O
In,O
addition,O
.,O
the,O
extent,O
of,O
drug,O
‐,O
induced,O
QT,O
prolongation,O
is,O
dependent,O
on,O
the,O
particular,O
drug,O
(,O
s,O
),O
involved,O
and,O
dosage,O
(,O
s,O
),O
of,O
the,O
drug,O
(,O
s,O
),O
.,O
Acetyl,O
‐,O
cholinesterase,O
inhibitors,O
may,O
have,O
vagotonic,O
effects,O
on,O
the,O
sinoatrial,O
and,O
atrioventricular,O
nodes,O
.,O
which,O
occasionally,O
mani,O
‐,O
fest,O
as,O
bradycardia,O
or,O
heart,O
block,O
(,O
<,O
2,PERCENT
%,PERCENT
),O
.,O
Because,O
bradycardia,O
is,O
a,O
risk,O
factor,O
for,O
torsade,O
de,O
pointes,O
.,O
a,O
theoretical,O
risk,O
exists,O
when,O
combined,O
with,O
agents,O
drug,O
interactions,O
with,O
psychotropic,O
agents,O
.,O
Favipiravir,O
(,O
FAVI,O
),O
is,O
an,O
anti,O
‐,O
viral,O
drug,O
[,O
used,O
in,O
severe,O
acute,O
respiratory,O
syndrome,O
(,O
SARS,O
),O
and,O
Middle,LOCATION
East,LOCATION
respiratory,O
syndrome,O
(,O
MERS,O
),O
],O
that,O
has,O
secured,O
approval,O
from,O
the,O
National,O
Med,O
‐,O
ical,O
Products,O
Administration,O
of,O
China,COUNTRY
to,O
treat,O
coronavirus,O
COVID,O
‐,O
19,NUMBER
.,O
An,O
open,O
‐,O
label,O
study,O
compared,O
FAVI,O
(,O
35,NUMBER
patients,O
),O
with,O
LPV,O
/,O
r,O
(,O
45,NUMBER
patients,O
),O
for,O
the,O
treatment,O
of,O
COVID,O
‐,O
19.31,NUMBER
FAVI,O
was,O
noted,O
to,O
have,O
shown,O
significantly,O
better,O
treatment,O
effects,O
on,O
COVID,O
‐,O
19,NUMBER
in,O
terms,O
of,O
disease,CAUSE_OF_DEATH
progression,O
and,O
viral,O
clearance,O
.,O
Available,O
dosage,O
information,O
.,O
Patients,O
in,O
the,O
study,O
received,O
oral,O
FAVI,O
(,O
day,DURATION
1,NUMBER
:,O
1600,NUMBER
mg,O
twice,O
daily,SET
;,O
day,DURATION
214,NUMBER
600,NUMBER
mg,O
twice,O
daily,SET
),O
plus,O
IFN,O
‐,O
by,O
aerosol,O
inhalation,O
(,O
5,NUMBER
million,NUMBER
U,O
twice,O
daily,SET
),O
or,O
LPV,O
/,O
r,O
(,O
days,DURATION
114,NUMBER
:,O
400,NUMBER
mg,O
/,O
100,NUMBER
mg,O
twice,O
daily,SET
plus,O
IFN,O
‐,O
by,O
aerosol,O
inhalation,O
(,O
5,NUMBER
million,NUMBER
U,O
twice,O
daily,SET
),O
.31,NUMBER
Adverse,O
effects,O
.,O
In,O
the,O
small,O
study,O
described,O
previously,DATE
.,O
two,NUMBER
patients,O
reported,O
diar,O
‐,O
rhoea,O
.,O
one,NUMBER
had,O
liver,O
injury,O
and,O
one,NUMBER
had,O
poor,CAUSE_OF_DEATH
diet,CAUSE_OF_DEATH
.31,NUMBER
Drug,O
inter,O
‐,O
actions,O
.,O
FAVI,ORGANIZATION
is,O
a,O
weak,O
inhibitor,O
of,O
CYPs,O
1A2,O
.,O
2C9,O
.,O
2C19,O
.,O
2D6,O
.,O
2E1,O
and,O
3A4,O
and,O
showed,O
little,O
or,O
no,O
induction,O
of,O
CYPs,O
1A2,O
.,O
2C9,O
.,O
2C19,O
and,O
3A4,O
in,O
human,O
hepatocytes,O
.,O
FAVI,O
inhibits,O
CYP2C8,O
and,O
cau,O
‐,O
tion,O
is,O
required,O
in,O
combination,O
with,O
drugs,CRIMINAL_CHARGE
metabolised,O
via,O
this,O
route,O
.,O
It,O
is,O
also,O
a,O
moderate,O
inhibitor,O
of,O
OAT1,O
and,O
OAT3,O
.,O
A,O
study,O
showed,O
increased,O
areas,O
under,O
the,O
plasma,O
concentration,O
‐,O
time,O
curves,O
(,O
AUC,O
),O
of,O
paracetamol,O
.,O
and,O
as,O
a,O
result,O
maximum,O
dose,O
should,O
be,O
3000,NUMBER
mg,O
/,O
day,DURATION
.,O
The,O
QT,O
interval,O
prolongation,O
risk,O
is,O
considered,O
to,O
be,O
low,O
with,O
FAVI,O
.9,NUMBER
Based,O
on,O
the,O
information,O
previously,DATE
mentioned,O
.,O
some,O
psychotropic,O
levels,O
are,O
expected,O
be,O
increased,O
due,O
to,O
weak,O
CYP,O
inhibition,O
by,O
FAVI,O
.,O
but,O
since,O
there,O
are,O
no,O
reports,O
of,O
this,O
.,O
they,O
are,O
not,O
therefore,O
be,O
required,O
but,O
it,O
is,O
important,O
to,O
be,O
aware,O
of,O
a,O
potential,O
interaction,O
.,O
Caution,O
is,O
recommended,O
when,O
FAVI,O
is,O
co,O
‐,O
administered,O
with,O
zopiclone,O
as,O
it,O
is,O
a,O
CYP2C8,O
sub,O
‐,O
strate,O
.,O
LPV,O
/,O
r,O
is,O
an,O
oral,O
antiretroviral,O
protease,O
inhibitor,O
cur,O
‐,O
rently,O
approved,O
for,O
the,O
treatment,O
of,O
HIV,CAUSE_OF_DEATH
infection,CAUSE_OF_DEATH
.,O
LPV,O
/,O
r,O
has,O
been,O
used,O
in,O
clinical,O
trials,O
for,O
the,O
treatment,O
of,O
COVID,O
‐,O
19,NUMBER
.,O
Re,O
‐,O
sults,O
from,O
one,NUMBER
small,O
case,O
series,O
found,O
that,O
evidence,O
of,O
clinical,O
benefit,O
with,O
LPV,O
/,O
r,O
was,O
equivocal,O
.32,NUMBER
A,O
randomised,O
controlled,O
trial,O
of,O
199,NUMBER
patients,O
in,O
China,COUNTRY
found,O
that,O
treatment,O
with,O
LPV,O
/,O
r,O
was,O
not,O
beneficial,O
compared,O
with,O
standard,O
care,O
alone,O
(,O
primary,O
outcome,O
was,O
time,O
to,O
improvement,O
),O
in,O
hospitalised,O
patients,O
with,O
severe,O
COVID,O
‐,O
19.12,NUMBER
Dosing,O
information,O
.,O
LPV,O
/,O
r,O
(,O
400,NUMBER
mg,O
and,O
100,NUMBER
mg,O
),O
orally,O
twice,O
daily,SET
.,O
plus,O
standard,O
care,O
for,O
14,DURATION
days,DURATION
was,O
used,O
in,O
the,O
clin,O
‐,O
ical,O
trial,O
.33,NUMBER
Adverse,O
effects,O
.,O
In,O
the,O
trial,O
.,O
gastrointestinal,O
ad,O
‐,O
verse,O
events,O
including,O
nausea,O
.,O
vomiting,O
and,O
diarrhoea,CAUSE_OF_DEATH
were,O
more,O
common,O
in,O
the,O
LPV,O
/,O
r,O
group,O
than,O
in,O
the,O
standard,O
‐,O
care,O
group,O
.,O
but,O
serious,O
adverse,O
events,O
were,O
more,O
common,O
in,O
the,O
standard,O
‐,O
care,O
group,O
.,O
Drug,O
interactions,O
.,O
Lopinavir,O
is,O
metabolised,O
extensively,O
by,O
the,O
hepatic,O
cytochrome,O
P450,O
system,O
.,O
almost,O
exclusively,O
by,O
CYP3A,O
.,O
Ritonavir,MISC
is,O
also,O
noted,O
to,O
be,O
extensively,O
metabolised,O
by,O
the,O
CYP3A,O
isozyme,O
family,O
and,O
to,O
a,O
lesser,O
extent,O
by,O
the,O
CYP2D6,O
isoform,O
.,O
Ritonavir,O
is,O
a,O
potent,O
CYP3A,O
and,O
CYP2D6,O
inhibitor,O
.,O
and,O
is,O
given,O
with,O
lopinavir,O
to,O
increase,O
plasma,O
levels,O
of,O
lopinavir,O
.,O
Ri,PERSON
‐,PERSON
tonavir,O
may,O
induce,O
glucuronidation,O
and,O
oxidation,O
by,O
CYP1A2,O
.,O
CYP2C8,O
.,O
CYP2C9,O
and,O
CYP2C19,O
.,O
thereby,O
increasing,O
the,O
biotransforma,O
‐,O
tion,O
of,O
some,O
drugs,CRIMINAL_CHARGE
metabolised,O
by,O
these,O
pathways,O
.,O
This,DATE
may,DATE
result,O
in,O
decreased,O
systemic,O
exposure,O
of,O
these,O
agents,O
.34,NUMBER
Therapeutic,O
Ad,O
‐,O
vances,O
in,O
Psychopharmacology,O
10,NUMBER
As,O
carbamazepine,O
is,O
a,O
potent,O
in,O
‐,O
ducer,O
and,O
a,O
substrate,O
of,O
CYP3A4,O
.,O
co,O
‐,O
administration,O
can,O
lead,O
to,O
both,O
reduced,O
LPV,O
/,O
r,O
levels,O
and,O
increased,O
carbamazepine,O
levels,O
.,O
Many,O
psychotropic,O
drugs,CRIMINAL_CHARGE
are,O
metabolised,O
by,O
CYP3A4,O
.,O
and,O
so,O
the,O
ma,O
‐,O
jority,O
will,O
experience,O
reduced,O
metabolism,O
and,O
increased,O
serum,O
levels,O
when,O
administered,O
with,O
LPV,O
/,O
r,O
(,O
see,O
highest,O
with,O
lurasidone,O
.,O
quetiapine,O
and,O
ziprasidone,O
.,O
and,O
these,O
combinations,O
should,O
be,O
avoided,O
.,O
In,O
contrast,O
.,O
the,O
following,O
psychotropics,O
are,O
expected,O
to,O
have,O
reduced,O
serum,O
levels,O
when,O
administered,O
with,O
LPV,O
/,O
r,O
:,O
olan,O
‐,O
zapine,O
.,O
agomelatine,O
.,O
bupropion,O
.,O
sertraline,O
.,O
lamotrigine,O
.,O
val,O
‐,O
proate,O
and,O
methadone,CAUSE_OF_DEATH
.,O
Of,O
the,O
psychotropics,O
evaluated,O
.,O
the,O
levels,O
of,O
the,O
following,O
drugs,CRIMINAL_CHARGE
are,O
not,O
expected,O
to,O
be,O
affected,O
:,O
amisul,O
‐,O
pride,O
.,O
sulpiride,O
.,O
phenelzine,O
.,O
lorazepam,O
.,O
oxazepam,O
.,O
lithium,O
.,O
ri,O
‐,O
vastigmine,O
.,O
memantine,O
and,O
pregabalin,LOCATION
.,O
For,O
duloxetine,O
and,O
paroxe,O
‐,O
tine,O
.,O
there,O
are,O
reports,O
of,O
both,O
increase,O
and,O
decrease,O
in,O
levels,O
when,O
given,O
with,O
LPV,O
/,O
r.,O
LPV,O
/,O
r,O
has,O
been,O
shown,O
to,O
cause,O
modest,O
asymptomatic,O
prolongation,O
of,O
the,O
PR,STATE_OR_PROVINCE
interval,O
in,O
some,O
healthy,O
adult,O
subjects,O
.,O
Rare,O
reports,O
of,O
2nd,ORDINAL
and,ORDINAL
3rd,ORDINAL
degree,O
atrioventricu,O
‐,O
lar,O
block,O
in,O
patients,O
with,O
underlying,O
structural,O
heart,CAUSE_OF_DEATH
disease,CAUSE_OF_DEATH
and,O
pre,O
‐,O
existing,O
conduction,O
system,O
abnormalities,O
in,O
patients,O
re,O
‐,O
ceiving,O
drugs,CRIMINAL_CHARGE
known,O
to,O
prolong,O
the,O
PR,STATE_OR_PROVINCE
interval,O
(,O
e.g.,O
verapamil,O
or,O
ATV,O
),O
have,O
been,O
reported,O
.,O
LPV,O
/,O
r,O
should,O
be,O
used,O
with,O
caution,O
in,O
such,O
patients,O
.9,NUMBER
As,O
many,O
antipsychotic,O
drugs,CRIMINAL_CHARGE
.,O
some,O
antidepressants,O
and,O
lithium,O
can,O
also,O
cause,O
cardiac,O
adverse,O
effects,O
.,O
co,O
‐,O
adminis,O
‐,O
tration,O
with,O
LPV,O
/,O
r,O
can,O
cause,O
pharmacodynamic,O
drug,O
interactions,O
leading,O
to,O
increased,O
cardiac,O
risks,O
.,O
In,O
addition,O
.,O
LPV,O
/,O
r,O
is,O
report,O
‐,O
ed,O
to,O
commonly,O
cause,O
respiratory,CAUSE_OF_DEATH
infections,CAUSE_OF_DEATH
and,O
neutropenia,O
.,O
both,O
of,O
these,O
will,O
be,O
added,O
risk,O
factors,O
in,O
patients,O
with,O
COVID,O
‐,O
19,NUMBER
.,O
especially,O
in,O
those,O
on,O
psychotropics,O
that,O
can,O
also,O
cause,O
neu,O
‐,O
tropenia,O
.,O
for,O
example,O
clozapine,O
and,O
carbamazepine,O
.,O
Nitazoxanide,PERSON
(,O
NITAZ,O
),O
an,O
antiprotozoal,O
that,O
is,O
currently,DATE
FDA,ORGANIZATION
approved,O
for,O
treating,O
cryptosporidium,O
and,O
giardia,O
shown,O
to,O
have,O
broad,O
antivi,O
‐,O
ral,O
activity,O
and,O
has,O
been,O
approved,O
in,O
some,O
countries,O
for,O
treating,O
noro,O
and,O
rota,O
viruses,O
.35,NUMBER
Proposed,O
dosing,O
regimen36,O
1,NUMBER
),O
HCLQ,O
400,NUMBER
mg,O
twice,O
a,DURATION
day,DURATION
for,O
23,DURATION
days,DURATION
(,O
loading,O
),O
then,O
200,NUMBER
mg,O
twice,O
a,DURATION
day,DURATION
for,O
2,NUMBER
),O
NITAZ,O
(,O
600,NUMBER
mg,O
‐,O
SR,O
tabs,O
),O
twice,O
a,DURATION
day,DURATION
;,O
if,O
unavailable,O
.,O
using,O
the,O
immediate,O
release,O
formulation,O
500,NUMBER
mg,O
three,NUMBER
times,O
a,DURATION
day,DURATION
for,O
7,DURATION
days,DURATION
(,O
absorption,O
better,O
with,O
food,O
),O
should,O
achieve,O
adequate,O
trough,O
lev,O
‐,O
els,O
that,O
easily,O
exceeds,O
the,O
EC50,O
of,O
SARS,O
‐,O
CoV2,O
.,O
The,O
duration,O
of,O
treatment,O
can,O
likely,O
be,O
adjusted,O
based,O
on,O
clinical,O
response,O
.,O
Ad,O
‐,O
verse,O
effects,O
.,O
NITAZ,ORGANIZATION
has,O
an,O
excellent,O
safety,O
record,O
.,O
though,O
some,O
gastrointestinal,O
adverse,O
effects,O
are,O
reported,O
.,O
Drug,O
interac,O
‐,O
tions,O
.,O
Although,O
no,O
drugdrug,O
interaction,O
studies,O
have,O
been,O
con,O
‐,O
ducted,O
in,O
vivo,O
.,O
it,O
is,O
expected,O
that,O
no,O
significant,O
interactions,O
would,O
occur,O
when,O
NITAZ,ORGANIZATION
is,O
co,O
‐,O
administered,O
with,O
drugs,CRIMINAL_CHARGE
that,O
either,O
are,O
metabolised,O
by,O
or,O
inhibit,O
CYP,O
450,NUMBER
enzymes,O
.,O
Caution,O
should,O
.,O
however,O
.,O
be,O
used,O
when,O
administering,O
NITAZ,O
concurrently,O
with,O
other,O
highly,O
plasma,O
protein,O
‐,O
bound,O
drugs,CRIMINAL_CHARGE
with,O
narrow,O
therapeutic,O
index,O
.,O
as,O
competition,O
for,O
binding,O
sites,O
may,O
occur,O
.,O
NITAZ,O
can,O
therefore,O
increase,O
adverse,O
effects,O
of,O
benzodiazepines,O
is,O
recommended,O
.,O
espe,O
‐,O
cially,O
with,O
regards,O
to,O
respiratory,O
depression,O
as,O
this,O
can,O
be,O
an,O
issue,O
in,O
patients,O
with,O
COVID,O
‐,O
19,NUMBER
.,O
who,O
already,O
may,O
be,O
experiencing,O
respiratory,O
distress,O
.,O
When,O
administered,O
with,O
food,O
.,O
the,O
AUC,O
of,O
NITAZ,ORGANIZATION
in,O
oral,O
form,O
increased,O
by,O
around,O
50,PERCENT
%,PERCENT
and,O
subsequently,O
is,O
recommended,O
to,O
be,O
taken,O
with,O
food,O
.,O
No,O
clinically,O
significant,O
ef,O
‐,O
fect,O
on,O
QTc,O
prolongation,O
has,O
been,O
observed,O
.9,NUMBER
Remdesivir,O
‐,O
GS,O
‐,O
5734,DATE
(,O
RDV,O
),O
is,O
a,O
novel,O
.,O
investigational,O
.,O
intravenous,O
nucleoside,O
ana,O
‐,O
logue,O
(,O
originally,O
used,O
to,O
treat,O
Ebola,O
),O
with,O
broad,O
antiviral,O
ac,O
‐,O
tivity,O
that,O
shows,O
in,O
vitro,O
activity,O
against,O
severe,O
acute,O
respira,O
‐,O
tory,O
syndrome,O
coronavirus,O
2,NUMBER
(,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
),O
.38,NUMBER
Several,O
clinical,O
tri,O
‐,O
als,O
with,O
RDV,O
are,O
underway,O
in,O
patients,O
with,O
mild,O
‐,O
to,O
‐,O
severe,O
COVID,O
‐,O
19.39,NUMBER
It,O
has,O
been,O
used,O
on,O
a,O
compassionate,O
‐,O
use,O
basis,O
in,O
ar,O
‐,O
eas,O
where,O
clinical,O
trials,O
are,O
not,O
available,O
;,O
however,O
.,O
the,O
manu,O
‐,O
facturer,O
has,O
paused,O
access,O
to,O
the,O
drug,O
via,O
this,O
route,O
due,O
to,O
overwhelming,O
demand,O
while,O
they,O
transition,O
to,O
an,O
expanded,O
access,O
programme,O
.,O
Exceptions,O
will,O
be,O
made,O
for,O
patients,O
with,O
severe,O
ill,O
‐,O
ness,O
.,O
and,O
pregnant,O
women,O
and,O
children,O
with,O
confirmed,O
infection,CAUSE_OF_DEATH
.40,NUMBER
D,O
Bishara,PERSON
.,O
C,O
Kalafatis,PERSON
et,O
al,O
.,O
In,O
a,O
recent,O
cohort,O
of,O
61,NUMBER
hospi,O
‐,O
talised,O
patients,O
who,O
received,O
RDV,O
on,O
a,O
compassionate,O
basis,O
.,O
clin,O
‐,O
ical,O
improvement,O
was,O
observed,O
in,O
36,NUMBER
of,O
53,NUMBER
patients,O
(,O
68,PERCENT
%,PERCENT
),O
.,O
A,O
total,O
of,O
25,NUMBER
patients,O
(,O
47,PERCENT
%,PERCENT
),O
were,O
discharged,O
.,O
and,O
7,NUMBER
patients,O
(,O
13,PERCENT
%,PERCENT
),O
died,O
.41,NUMBER
Dosing,O
information,O
.,O
Limited,O
data,O
available,O
;,O
dosing,O
used,O
in,O
clinical,O
trials,O
:,O
200,NUMBER
mg,O
as,O
a,O
single,O
dose,O
on,O
day,DURATION
1,NUMBER
.,O
followed,O
by,O
100,NUMBER
mg,O
once,DATE
daily,SET
until,O
day,DURATION
5,NUMBER
or,O
10,NUMBER
in,O
addition,O
to,O
standard,O
care,O
.42.43,NUMBER
Adverse,O
effects,O
.,O
The,O
information,O
on,O
adverse,O
effects,O
is,O
also,O
limited,O
however,O
it,O
has,O
been,O
reported,O
to,O
cause,O
nausea,O
and,O
in,O
‐,O
crease,O
liver,O
enzymes,O
(,O
which,O
may,O
or,O
may,O
not,O
indicate,O
liver,O
dam,O
‐,O
age,O
),O
.,O
It,O
does,O
not,O
prolong,O
QTc,O
interval,O
.44,NUMBER
Drug,O
interactions,O
.,O
Based,O
on,O
rapid,O
distribution,O
.,O
metabolism,O
and,O
clearance,O
.,O
the,O
like,O
‐,O
lihood,O
of,O
clinically,O
significant,O
interactions,O
is,O
low,O
.,O
RDV,O
is,O
a,O
substrate,O
of,O
CYP,O
2C8,O
.,O
CYP,O
2D6,O
.,O
CYP,O
3A4,O
and,O
transporters,O
OATP1B1,O
and,O
P,O
‐,O
gp,O
in,O
vitro,O
.,O
but,O
coadministration,O
with,O
inhibitors,O
of,O
these,O
CYP,O
isoforms,O
and,O
transporters,O
is,O
unlikely,O
to,O
increase,O
its,O
lev,O
‐,O
els,O
.9,NUMBER
RDV,O
can,O
be,O
impacted,O
by,O
strong,O
inducers,O
(,O
e.g.,O
carbamazepine,O
),O
thus,O
co,O
‐,O
administration,O
is,O
not,O
recommended,O
.,O
RDV,O
is,O
an,O
inducer,O
of,O
CYP,O
1A2,O
and,O
CYP,O
2B6,O
in,O
vitro,O
but,O
.,O
considering,O
the,O
exposure,O
.,O
it,O
is,O
unlikely,O
to,O
translate,O
into,O
clinically,O
significant,O
interaction,O
with,O
substrates,O
of,O
these,O
enzymes,O
.9,NUMBER
However,O
.,O
caution,O
should,O
be,O
used,O
when,O
co,O
‐,O
administered,O
with,O
clozapine,O
(,O
CYP1A2,O
substrate,O
),O
and,O
methadone,CAUSE_OF_DEATH
(,O
CYP2B6,O
substrate,O
),O
as,O
.,O
theoretically,O
.,O
for,O
effects,O
on,O
other,O
psychotropics,O
as,O
well,O
),O
.,O
Since,O
there,O
are,O
limited,O
data,O
on,O
the,O
tolerability,O
and,O
adverse,O
effect,O
profile,O
of,O
RDV,O
.,O
it,O
is,O
diffi,O
‐,O
cult,RELIGION
to,O
predict,O
whether,O
any,O
pharmacodynamic,O
interactions,O
with,O
psychotropics,O
exist,O
.,O
Reports,O
of,O
increased,O
liver,O
enzymes,O
may,O
sug,O
‐,O
gest,O
that,O
monitoring,O
may,O
be,O
warranted,O
in,O
some,O
patients,O
.,O
especial,O
‐,O
ly,O
if,O
co,O
‐,O
prescribed,O
psychotropics,O
that,O
can,O
also,O
increase,O
liver,O
enzymes,O
or,O
affect,O
liver,O
function,O
for,O
example,O
.,O
agomelatine,O
.,O
monoamine,O
oxidase,O
inhibitors,O
.,O
carbamazepine,O
or,O
haloperidol,O
.,O
Rib,O
‐,O
avirin,O
(,O
RBV,O
),O
is,O
an,O
antiviral,O
used,O
to,O
treat,O
hepatitis,O
and,O
has,O
been,O
used,O
previously,DATE
to,O
manage,O
SARS,O
and,O
MERS,O
patients,O
.,O
An,O
open,O
‐,O
label,O
.,O
randomised,O
controlled,O
trial,O
currently,DATE
underway,O
in,O
China,COUNTRY
included,O
three,NUMBER
regimens,O
with,O
the,O
following,O
RBV,O
(,O
intravenous,O
loading,O
dose,O
of,O
2,NUMBER
g,O
.,O
followed,O
by,O
oral,O
doses,O
of,O
400600,NUMBER
mg,O
every,O
8,NUMBER
h,O
depending,O
on,O
the,O
patients,O
weight,O
.,O
for,O
14,DURATION
days,DURATION
),O
;,O
LPV,O
/,O
r,O
(,O
oral,O
.,O
400,NUMBER
mg,O
/,O
100,NUMBER
mg,O
per,O
dose,O
.,O
twice,O
a,DURATION
day,DURATION
.,O
for,O
14,DURATION
days,DURATION
),O
;,O
IFN,O
‐‐,O
1b,NUMBER
(,O
atomizing,O
inhala,O
‐,O
tion,O
.,O
5,NUMBER
million,NUMBER
U,O
or,O
50,NUMBER
g,O
per,O
dose,O
.,O
twice,O
a,DURATION
day,DURATION
.,O
for,O
14,DURATION
days,DURATION
),O
.,O
And,O
comparing,O
the,O
effectiveness,O
of,O
:,O
RBV,O
plus,O
IFN,O
‐,O
1b,NUMBER
(,O
arm,O
A,O
),O
;,O
LPV,O
/,O
r,O
plus,O
IFN,O
‐,O
1b,NUMBER
(,O
arm,O
B,O
),O
;,O
and,O
RBV,O
plus,O
LPV,O
/,O
r,O
plus,O
IFN,O
‐,O
1b,NUMBER
(,O
arm,O
C,O
),O
for,O
the,O
treatment,O
of,O
COVID,O
‐,O
19,NUMBER
.,O
Adverse,O
effects46,O
.,O
Pancytopenia,O
and,O
bone,O
marrow,O
suppression,O
have,O
been,O
reported,O
with,O
RBV,O
.,O
No,O
ef,O
‐,O
fect,O
on,O
QTc,O
prolongation,O
has,O
been,O
observed,O
.,O
There,O
are,O
several,O
serious,O
adverse,O
reactions,O
associated,O
with,O
the,O
combination,O
therapy,O
of,O
RBV,O
with,O
(,O
peg,O
),O
IFN,O
‐,O
.,O
These,O
include,O
:,O
‐,O
Severe,O
psychiatric,O
and,O
central,O
nervous,O
system,O
effects,O
(,O
such,O
as,O
depression,O
.,O
suicidal,O
ideation,O
.,O
attempted,O
suicide,CAUSE_OF_DEATH
and,O
aggressive,O
behaviour,O
.,O
etc.,O
),O
;,O
‐,O
Severe,O
ocular,O
disorders,O
;,O
‐,O
Dental,O
and,O
periodontal,O
disorders,O
.,O
Drug,O
interactions,O
.,O
RBV,O
has,O
two,NUMBER
pathways,O
of,O
metabolism,O
:,O
a,O
re,O
‐,O
versible,O
phosphorylation,O
pathway,O
and,O
a,O
degradative,O
pathway,O
.,O
Both,O
RBV,O
and,O
metabolites,O
are,O
excreted,O
renally,O
.,O
Results,O
of,O
in,O
vitro,O
studies,O
indicated,O
no,O
CYP,O
450,NUMBER
enzyme,O
‐,O
mediated,O
metabolism,O
of,O
RBV,O
.,O
RBV,O
does,O
not,O
inhibit,O
CYP,O
450,NUMBER
enzymes,O
and,O
there,O
is,O
no,O
evidence,O
from,O
toxicity,O
studies,O
that,O
it,O
induces,O
liver,O
enzymes,O
.,O
therefore,O
potential,O
for,O
P450,O
‐,O
based,O
interactions,O
is,O
minimal,O
.9,NUMBER
Information,O
on,O
drug,O
interactions,O
with,O
RBV,O
is,O
limited,O
.,O
The,O
Drugbank,O
database,O
lists,O
potential,O
pharmacokinetic,O
drug,O
interactions,O
leading,O
to,O
in,O
‐,O
creased,O
RBV,O
levels,O
with,O
the,O
following,O
psychotropic,O
agents,O
:,O
cloza,O
‐,O
pine,O
.,O
haloperidol,O
.,O
amitriptyline,O
.,O
duloxetine,O
.,O
imipramine,O
.,O
phenelzine,O
.,O
venlafaxine,O
.,O
midazolam,O
.,O
lamotrigine,O
and,O
pregabalin,LOCATION
.,O
It,O
is,O
not,O
clear,O
whether,O
these,O
are,O
actual,O
reports,O
of,O
interactions,O
or,O
theoretical,O
considerations,O
.,O
and,O
the,O
mechanisms,O
are,O
not,O
clear,O
.,O
Similarly,O
.,O
Drugbank,PERSON
also,O
notes,O
that,O
RBV,O
may,O
lead,O
to,O
increased,O
levels,O
of,O
the,O
following,O
psychotropic,O
agents,O
:,O
paliperidone,O
.,O
queti,O
‐,O
apine,O
.,O
bupropion,O
.,O
clomipramine,O
.,O
desipramine,O
.,O
vortioxetine,O
.,O
clon,O
‐,O
azepam,O
.,O
diazepam,O
.,O
oxazepam,O
.,O
carbamazepine,O
and,O
lithium,O
.,O
Therapeu,O
‐,O
tic,O
Advances,O
in,O
Psychopharmacology,O
10,NUMBER
Pharmacodynamic,O
interac,O
‐,O
tions,O
with,O
psychotropics,O
include,O
infections,CAUSE_OF_DEATH
and,O
neutropenia,O
.,O
which,O
have,O
both,O
been,O
reported,O
with,O
RBV,O
use,O
a,O
significant,O
risk,O
for,O
patients,O
infected,O
with,O
COVID,O
‐,O
19,NUMBER
.,O
particularly,O
if,O
also,O
taking,O
clozapine,O
or,O
carbamazepine,O
.,O
also,O
known,O
to,O
cause,O
neutropenia,O
.,O
In,O
addition,O
.,O
combination,O
therapy,O
of,O
RBV,O
with,O
(,O
peg,O
),O
IFN,O
‐,O
has,O
been,O
as,O
‐,O
sociated,O
with,O
severe,O
psychiatric,O
effects,O
.,O
another,O
serious,O
concern,O
if,O
used,O
in,O
psychiatric,O
patients,O
.,O
Tocilizumab,PERSON
(,O
TCZ,O
),O
is,O
an,O
inter,O
‐,O
leukin,O
(,O
IL,STATE_OR_PROVINCE
),O
‐,O
6,NUMBER
receptor,O
inhibiting,O
monoclonal,O
antibody,O
that,O
is,O
currently,DATE
approved,O
for,O
rheumatological,O
conditions,O
such,O
as,O
rheuma,O
‐,O
toid,O
arthritis,O
and,O
cytokine,O
release,O
syndrome,O
.,O
TCZ,O
is,O
being,O
tri,O
‐,O
alled,O
in,O
patients,O
with,O
severe,O
COVID,O
‐,O
19,NUMBER
to,O
see,O
whether,O
it,O
is,O
ef,O
‐,O
fective,O
in,O
reducing,O
the,O
virus,O
‐,O
induced,O
cytokine,O
storm,CAUSE_OF_DEATH
.,O
thereby,O
po,O
‐,O
tentially,O
reducing,O
complications,CAUSE_OF_DEATH
.47,NUMBER
However,O
.,O
the,O
decision,O
to,O
sup,O
‐,O
press,O
the,O
immune,O
system,O
of,O
a,O
critically,O
unwell,O
patient,O
with,O
COVID19,O
is,O
a,O
difficult,O
one,NUMBER
;,O
the,O
beneficial,O
anti,O
‐,O
inflammatory,O
ef,O
‐,O
fects,O
of,O
TCZ,O
(,O
or,O
any,O
other,O
anti,O
‐,O
inflammatory,O
drug,O
),O
must,O
be,O
weighed,O
against,O
the,O
possibly,O
detrimental,O
effects,O
of,O
impairment,O
of,O
immunity,O
.48,NUMBER
Patients,O
with,O
COVID,O
‐,O
19,NUMBER
experience,O
an,O
elevation,O
of,O
IL,STATE_OR_PROVINCE
‐,O
6,NUMBER
.,O
However,O
.,O
since,O
co,O
‐,O
medication,O
will,O
not,O
have,O
been,O
adjusted,O
to,O
the,O
acute,O
inflammatory,O
COVID,O
‐,O
19,NUMBER
state,O
.,O
and,O
since,O
treatment,O
with,O
TCZ,O
would,O
have,O
been,O
initiated,O
very,O
rapidly,O
(,O
and,O
only,O
up,O
to,O
two,NUMBER
doses,O
given,O
),O
.,O
no,O
prior,O
adjustment,O
of,O
CYP,O
substrates,O
is,O
needed,O
.,O
But,O
the,O
effect,O
of,O
acute,O
COVID,O
‐,O
19,NUMBER
infection,CAUSE_OF_DEATH
on,O
drugs,CRIMINAL_CHARGE
with,O
narrow,O
therapeutic,O
index,O
is,O
unclear,O
.9,NUMBER
TCZ,O
may,O
decrease,O
blood,O
levels,O
of,O
carbamazepine,O
.,O
which,O
may,O
require,O
dose,O
Caution,O
is,O
required,O
when,O
co,O
‐,O
administering,O
with,O
myelotoxic,O
drugs,CRIMINAL_CHARGE
such,O
as,O
clozapine,O
or,O
car,O
‐,O
bamazepine,O
due,O
to,O
the,O
potential,O
additive,O
haematological,O
toxicity,O
.,O
No,O
clinically,O
significant,O
effect,O
on,O
QT,O
prolongation,O
was,O
observed,O
in,O
healthy,O
subjects,O
.9,NUMBER
Other,O
drugs,CRIMINAL_CHARGE
Intravenous,O
immunoglobulin,O
is,O
being,O
trialled,O
in,O
some,O
patients,O
with,O
COVID,O
‐,O
19,NUMBER
;,O
however,O
.,O
there,O
are,O
no,O
data,O
to,O
support,O
this,O
.,O
Angiotensin,O
‐,O
II,NUMBER
receptor,O
antagonists,O
such,O
as,O
losartan,O
are,O
being,O
investigated,O
as,O
a,O
potential,O
treatment,O
be,O
‐,O
cause,O
it,O
is,O
thought,O
that,O
the,O
angiotensin,O
‐,O
converting,O
enzyme,O
‐,O
2,NUMBER
(,O
ACE2,O
),O
receptor,O
is,O
the,O
main,O
binding,O
site,O
for,O
the,O
virus,O
.35.36,NUMBER
Re,O
‐,O
ported,O
dosage,O
has,O
been,O
:,O
The,O
initial,O
dose,O
should,O
be,O
48,NUMBER
mg,O
/,O
kg,O
.,O
with,O
the,O
recommended,O
dosage,O
being,O
400,NUMBER
mg,O
;,O
Dilute,O
with,O
0.9,PERCENT
%,PERCENT
saline,O
to,O
100,NUMBER
ml,O
and,O
infuse,O
over,O
the,O
course,O
of,O
more,O
than,O
1,NUMBER
h,O
;,O
Repeat,O
once,DATE
after,O
12,NUMBER
h,O
(,O
same,O
dosage,O
),O
if,O
the,O
response,O
to,O
the,O
first,ORDINAL
dose,O
was,O
poor,O
.,O
maximum,O
two,NUMBER
cumulative,O
doses,O
;,O
Single,O
maximum,O
dose,O
is,O
800,NUMBER
mg,O
.,O
Drug,O
interactions,O
.,O
TCZ,O
has,O
no,O
direct,O
inhibitory,O
or,O
inducing,O
effects,O
on,O
CYP,O
enzymes,O
per,O
se,O
.,O
However,O
.,O
it,O
reverses,O
IL,STATE_OR_PROVINCE
‐,O
6,NUMBER
induced,O
suppression,O
of,O
cytochromes,O
(,O
elevation,O
of,O
IL,STATE_OR_PROVINCE
‐,O
6,NUMBER
during,O
inflammation,O
has,O
been,O
shown,O
to,O
inhibit,O
CYP,O
3A4,O
.,O
CYP2C19,O
.,O
CUP2C9,O
and,O
CYP1A2,O
ac,O
‐,O
tivity,O
.,O
resulting,O
in,O
higher,O
drug,O
exposure,O
of,O
substrate,O
drugs,CRIMINAL_CHARGE
),O
.,O
which,O
.,O
prior,O
to,O
treatment,O
with,O
TCZ,O
.,O
has,O
been,O
adjusted,O
to,O
the,O
me,O
‐,O
tabolism,O
of,O
individuals,O
.,O
When,O
treatment,O
with,O
TCZ,O
is,O
started,O
.,O
cy,O
‐,O
tochrome,O
activity,O
normalises,O
.,O
thus,O
leading,O
to,O
reduced,O
exposure,O
of,O
drugs,CRIMINAL_CHARGE
.,O
which,O
.,O
prior,O
to,O
treatment,O
.,O
had,O
been,O
adjusted,O
to,O
the,O
metab,O
‐,O
olism,O
of,O
individuals,O
with,O
the,O
rheumatic,O
disease,CAUSE_OF_DEATH
that,O
it,O
is,O
usual,O
‐,O
ly,O
used,O
for,O
.9,NUMBER
In,O
addition,O
.,O
researchers,O
at,O
the,O
Murdoch,PERSON
set,O
to,O
con,O
‐,O
duct,O
a,O
randomised,O
.,O
multi,O
‐,O
centre,O
clinical,O
trial,O
to,O
test,O
the,O
use,O
of,O
tuberculosis,CAUSE_OF_DEATH
vaccine,O
BCG,O
against,O
Covid,O
‐,O
19,NUMBER
.,O
The,O
BRACE,O
trial,O
is,O
in,O
‐,O
tended,O
for,O
healthcare,O
workers,O
.,O
It,O
is,O
based,O
on,O
previous,O
study,O
findings,O
that,O
BCG,ORGANIZATION
decreases,O
the,O
level,O
of,O
virus,O
in,O
patients,O
in,O
‐,O
fected,O
by,O
viruses,O
similar,O
to,O
SARS,O
‐,O
CoV,O
‐,O
2.49,NUMBER
BCG,O
vaccines,O
heterolo,O
‐,O
gous,O
beneficial,O
effect,O
against,O
non,O
‐,O
tuberculosis,CAUSE_OF_DEATH
infections,CAUSE_OF_DEATH
is,O
well,O
known,O
.,O
The,O
vaccine,O
works,O
on,O
the,O
innate,O
immune,O
system,O
and,O
produces,O
a,O
memory,O
like,O
response,O
termed,O
trained,O
immunity,O
that,O
helps,O
in,O
faster,O
recognition,O
.,O
triggering,O
a,O
quicker,O
inflammatory,O
response,O
.,O
Recent,O
studies,O
have,O
also,O
suggested,O
that,O
it,O
has,O
the,O
po,O
‐,O
tential,O
to,O
protect,O
against,O
experimental,O
infection,CAUSE_OF_DEATH
with,O
yellow,O
fever,CAUSE_OF_DEATH
vaccine,O
strain,O
and,O
to,O
enhance,O
immune,O
responses,O
to,O
other,O
vaccines,O
in,O
general,TITLE
including,O
influenza,CAUSE_OF_DEATH
vaccination,O
.50,NUMBER
We,O
urge,O
clinicians,O
to,O
exercise,O
significant,O
caution,O
in,O
the,O
use,O
of,O
any,O
of,O
the,O
previously,DATE
mentioned,O
medications,O
even,O
on,O
a,O
compassionate,O
‐,O
use,O
basis,O
in,O
the,O
absence,O
of,O
adequately,O
powered,O
and,O
/,O
or,O
D,O
Bishara,PERSON
.,O
C,O
Kalafatis,PERSON
et,O
al,O
.,O
trials,O
for,O
the,O
treatment,O
of,O
COVID,O
‐,O
19,NUMBER
patients,O
.,O
An,O
even,O
higher,O
threshold,O
of,O
vigilance,O
should,O
be,O
maintained,O
for,O
patients,O
with,O
pre,O
‐,O
existing,O
conditions,O
and,O
older,O
adults,O
due,O
to,O
added,O
toxicity,O
and,O
many,O
psychotropic,O
agents,O
can,O
interact,O
with,O
agents,O
used,O
in,O
COVID,O
‐,O
19,NUMBER
.,O
leading,O
to,O
serious,O
adverse,O
effects,O
in,O
‐,O
cluding,O
QTc,O
prolongation,O
thus,O
increasing,O
the,O
risk,O
of,O
torsades,O
de,O
pointes,O
and,O
bone,O
marrow,O
suppression,O
.,O
Identifying,O
and,O
avoiding,O
these,O
interactions,O
can,O
be,O
vital,O
to,O
improving,O
survival,O
in,O
COVID,O
‐,O
19,NUMBER
patients,O
.,O
Conflict,O
of,O
interest,O
statement,O
Delia,PERSON
Bishara,PERSON
David,PERSON
Taylor,PERSON
1,NUMBER
.,O
Kalil,PERSON
AC,O
.,O
Treating,O
COVID,O
‐,O
19,NUMBER
‐,O
off,O
‐,O
label,O
drug,O
use,O
.,O
compas,O
‐,O
sionate,O
use,O
.,O
and,O
randomized,O
2,NUMBER
.,O
Sayburn,O
A.,O
Covid,O
‐,O
19,NUMBER
:,O
trials,O
of,O
four,NUMBER
potential,O
treatments,O
to,O
generate,O
robust,O
data,O
of,O
what,O
works,O
.,O
BMJ,O
2020,DATE
;,O
368,NUMBER
:,O
m1206,O
.,O
3,NUMBER
.,O
Recovery,O
:,O
Randomised,O
Evaluation,O
of,O
COVID19,O
Therapy,O
.,O
This,O
nation,O
clinical,O
trials,O
aims,O
to,O
identify,O
treatments,O
that,O
may,O
be,O
beneficial,O
for,O
4,NUMBER
.,O
Medicines,O
Complete,O
.,O
Stockleys,O
interactions,O
checker,TITLE
.,O
stockleys,O
‐,O
interactions,O
‐,O
checker,TITLE
/,O
(,O
accessed,O
06,DATE
May,DATE
5,DATE
.,O
HIV,CAUSE_OF_DEATH
Drug,O
Interactions,O
.,O
Interaction,O
10,NUMBER
.,O
Medicines.org.uk,URL
.,O
Azithromycin,MISC
250,NUMBER
mg,O
capsules,O
.,O
PROPS,O
(,O
accessed,O
02,DATE
April,DATE
2020,DATE
),O
.,O
prevention,O
of,O
coronavirus,O
disease,CAUSE_OF_DEATH
(,O
COVID,O
‐,O
19,NUMBER
),O
12,NUMBER
.,O
Expert,O
consensus,O
on,O
chloroquine,O
phosphate,O
for,O
the,O
treatment,O
of,O
novel,O
coronavirus,O
pneumonia,CAUSE_OF_DEATH
.,O
Zhonghua,PERSON
Jie,PERSON
He,PERSON
He,PERSON
Hu,PERSON
Xi,PERSON
Za,PERSON
Zhi,PERSON
2020,DATE
;,O
43,NUMBER
:,O
13,NUMBER
.,O
Gautret,O
P,O
.,O
Lagier,PERSON
JC,PERSON
.,O
Parola,PERSON
P,O
.,O
et,O
al,O
.,O
Hydroxy,O
‐,O
chloroquine,O
and,O
azithromycin,O
as,O
a,O
treatment,O
of,O
COVID,O
‐,O
19,NUMBER
:,O
results,O
of,O
an,O
open,O
‐,O
label,O
non,O
‐,O
randomized,O
clinical,O
trial,O
.,O
Int,PERSON
J,PERSON
Antimicrob,PERSON
14,NUMBER
.,O
Molina,PERSON
JM,PERSON
.,O
Delaugerre,PERSON
C,PERSON
.,O
Goff,PERSON
JL,O
.,O
et,O
al,O
.,O
No,O
evidence,O
of,O
rapid,O
antiviral,O
clearance,O
or,O
clinical,O
benefit,O
with,O
the,O
combina,O
‐,O
tion,O
of,O
hydroxychloroquine,O
and,O
azithromycin,O
in,O
patients,O
with,O
se,O
‐,O
vere,O
COVID,O
‐,O
19,NUMBER
Infection,CAUSE_OF_DEATH
.,O
Med,O
Mal,O
15,NUMBER
.,O
Chen,PERSON
J,PERSON
.,O
Liu,PERSON
D,PERSON
.,O
Liu,PERSON
L,O
.,O
et,O
al,O
.,O
A,O
pilot,TITLE
study,O
of,O
hydroxychloroquine,O
in,O
treatment,O
of,O
patients,O
with,O
common,O
coronavirus,O
disease,CAUSE_OF_DEATH
‐,O
19,NUMBER
(,O
COVID,O
‐,O
19,NUMBER
),O
.,O
J,O
Zhejiang,STATE_OR_PROVINCE
Univ,O
2020,DATE
;,O
49,NUMBER
:,O
215219,NUMBER
.,O
16,NUMBER
.,O
Chen,O
Z,O
.,O
Hu,PERSON
J,PERSON
.,O
Zhang,PERSON
Z,PERSON
.,O
et,O
al,O
.,O
Efficacy,O
of,O
hy,O
‐,O
droxychloroquine,O
in,O
patients,O
with,O
COVID,O
‐,O
19,NUMBER
:,O
results,O
of,O
a,O
random,O
‐,O
ized,O
clinical,O
trial,O
.,O
medRxiv,O
17,NUMBER
.,O
Chorin,O
E,O
.,O
Dai,PERSON
M,O
.,O
Shulman,PERSON
E,O
.,O
et,O
al,O
.,O
The,O
QT,O
interval,O
in,O
patients,O
with,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
infection,CAUSE_OF_DEATH
treated,O
with,O
hydroxychloroquine,O
/,O
azithromycin,O
.,O
Therapeutic,O
Advances,O
in,O
Psychopharmacology,O
10,NUMBER
18,NUMBER
.,O
BMJ,O
.,O
Rapid,O
response,O
:,O
use,O
of,O
hydroxy,O
‐,O
chloroquine,O
19,NUMBER
.,O
Schrezenmeier,O
E,O
and,O
Dorner,PERSON
T.,O
Mechanisms,O
of,O
ac,O
‐,O
tion,O
of,O
hydroxychloroquine,O
and,O
chloroquine,O
:,O
implications,O
for,O
rheumatology,O
.,O
Nat,PERSON
Rev,PERSON
20,NUMBER
.,O
Zhou,PERSON
D,PERSON
.,O
Dai,PERSON
SM,O
and,O
Tong,O
Q.,O
COVID,O
‐,O
19,NUMBER
:,O
a,O
recommendation,O
to,O
examine,O
the,O
effect,O
of,O
hydroxychloroquine,O
in,O
preventing,O
infection,CAUSE_OF_DEATH
and,O
21,NUMBER
.,O
U.S.,ORGANIZATION
Food,ORGANIZATION
&,ORGANIZATION
Drug,ORGANIZATION
Administration,ORGANIZATION
.,O
Hydrochloroquine,O
or,O
chloroquine,O
for,O
COVID,O
‐,O
19,NUMBER
:,O
drug,O
safety,O
commu,O
‐,O
nication,O
FDA,ORGANIZATION
cautions,O
against,O
use,O
outside,O
of,O
the,O
hospital,O
setting,O
or,O
a,O
clinical,O
trial,O
due,O
to,O
hydroxychloroquine,O
‐,O
or,O
‐,O
chloroquine,O
‐,O
covid,O
‐,O
19drug,NUMBER
‐,O
safety,O
‐,O
communication,O
‐,O
fda,O
‐,O
cautions,O
‐,O
againstuse,O
(,O
ac,O
‐,O
cessed,O
02,DATE
May,DATE
2020,DATE
),O
.,O
22,NUMBER
.,O
Liu,PERSON
X,PERSON
.,O
Li,PERSON
Z,PERSON
.,O
Liu,PERSON
Z,PERSON
.,O
et,O
al,O
.,O
Potential,O
therapeutic,O
effects,O
of,O
dipyridamole,O
in,O
the,O
severely,O
ill,O
patients,O
product,O
/,O
3557,DATE
/,O
smpc,O
(,O
accessed,O
05,DATE
May,DATE
2020,DATE
),O
.,O
dipyridamole.html,O
(,O
ac,O
‐,O
cessed,O
05,DATE
May,DATE
2020,DATE
),O
.,O
31,NUMBER
.,O
Cai,O
Q,O
.,O
Yang,PERSON
M,O
.,O
Liu,PERSON
D,O
.,O
et,O
al,O
.,O
Experimen,O
‐,O
tal,O
treatment,O
with,O
favipiravir,O
for,O
COVID,O
‐,O
19,NUMBER
:,O
an,O
open,O
‐,O
label,O
con,O
‐,O
trol,O
study,O
.,O
Engineering,O
(,O
Beijing,CITY
),O
.,O
32,NUMBER
.,O
Young,O
BE,O
.,O
Ong,PERSON
SWX,PERSON
.,O
Kalimuddin,PERSON
S,PERSON
.,O
et,O
al,O
.,O
Epidemiologic,O
features,O
and,O
clinical,O
course,O
of,O
patients,O
infected,O
with,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
in,O
Singapore,COUNTRY
.,O
33,NUMBER
.,O
Cao,PERSON
B,PERSON
.,O
Wang,O
Y,O
.,O
Wen,PERSON
D,PERSON
.,O
et,O
al,O
.,O
A,O
trial,O
of,O
lopinavirritonavir,O
in,O
adults,O
hospitalized,O
with,O
34,NUMBER
.,O
Medicines.org.uk,URL
.,O
Norvir,MISC
100,NUMBER
mg,O
film,O
‐,O
coated,O
product,O
/,O
510,NUMBER
/,O
smpc,O
(,O
accessed,O
03,DATE
March,DATE
2020,DATE
),O
.,O
35,NUMBER
.,O
Rossignol,ORGANIZATION
JF,ORGANIZATION
.,O
Ni,MISC
‐,O
tazoxanide,O
:,O
a,O
first,ORDINAL
‐,O
in,O
‐,O
class,O
broadspectrum,O
antiviral,O
agent,O
.,O
An,O
‐,O
tivir,O
Res,O
2014,DATE
;,O
110,NUMBER
:,O
36,NUMBER
.,O
Padmanabhan,PERSON
S.,PERSON
Potential,PERSON
dual,O
therapeu,O
‐,O
tic,O
approach,O
against,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
/,O
COVID,O
‐,O
19,NUMBER
with,O
Nitazoxanide,O
and,O
Hydroxychloroquine,O
.,O
2020,DATE
.,O
37,NUMBER
.,O
Yao,PERSON
X,PERSON
.,O
Ye,PERSON
F,PERSON
.,O
Zhang,O
M,O
.,O
et,O
al,O
.,O
In,O
vitro,O
antiviral,O
activity,O
and,O
projection,O
of,O
optimized,O
dosing,O
de,O
‐,O
sign,O
of,O
hydroxychloroquine,O
for,O
the,O
treatment,O
of,O
severe,O
acute,O
res,O
‐,O
piratory,O
syndrome,O
coronavirus,O
2,NUMBER
(,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
),O
.,O
Clin,O
Infect,O
Dis,O
.,O
38,NUMBER
.,O
Wang,PERSON
M,O
.,O
Cao,PERSON
R,PERSON
.,O
Zhang,PERSON
L,PERSON
.,O
et,O
al,O
.,O
Remdesivir,O
and,O
chloroquine,O
ef,O
‐,O
fectively,O
inhibit,O
the,O
recently,DATE
emerged,O
novel,O
coronavirus,O
(,O
2019,DATE
‐,O
nCoV,O
),O
in,O
vitro,O
.,O
Cell,O
Res,O
2020,DATE
;,O
30,NUMBER
:,O
269271,NUMBER
.,O
PROPS,O
(,O
ac,O
‐,O
cessed,O
05,DATE
May,DATE
2020,DATE
),O
.,O
city,O
=,O
&,O
dist,O
=,O
&,O
Search,O
=,O
Search,O
(,O
accessed,O
27,NUMBER
March,DATE
27,DATE
.,O
Borrell,PERSON
B.,PERSON
New,PERSON
York,PERSON
clinical,O
trial,O
quietly,O
tests,O
heart,O
‐,O
burn,O
remedy,O
against,O
coronavirus,O
.,O
Science,O
.,O
29,NUMBER
.,O
Taylor,PERSON
D,O
.,O
Barnes,PERSON
TRE,O
and,O
Young,O
AH,O
.,O
The,O
Maudsley,O
prescribing,O
guidelines,O
in,O
psychia,O
‐,O
try,O
.,O
13th,ORDINAL
ed,O
.,O
Hoboken,CITY
.,O
NJ,STATE_OR_PROVINCE
:,O
Wiley,PERSON
.,O
2018,DATE
.,O
40,NUMBER
.,O
BMJ,O
Best,O
Practice,O
.,O
Coronavirus,O
disease,CAUSE_OF_DEATH
2019,DATE
41,DATE
.,O
Grein,PERSON
J,PERSON
.,O
Norio,PERSON
Ohmagari,PERSON
N,PERSON
.,O
Shin,PERSON
D,PERSON
.,O
et,O
al,O
.,O
Compassionate,O
use,O
of,O
remdesivir,O
for,O
patients,O
D,O
Bishara,PERSON
.,O
C,O
Kalafatis,PERSON
et,O
al,O
.,O
alphain,O
in,O
patients,O
with,O
mild,O
to,O
moderate,O
novel,O
coronavirus,O
pneumonia,CAUSE_OF_DEATH
.,O
Chin,PERSON
Med,PERSON
J,PERSON
(,O
Engl,ORGANIZATION
),O
2020,DATE
;,O
42,NUMBER
.,O
Gilead,ORGANIZATION
sci,O
‐,O
ences,O
initiates,O
two,NUMBER
phase,O
3,NUMBER
studies,O
of,O
investigational,O
antiviral,O
remdesivir,O
for,O
the,O
gilead,O
‐,O
sciences,O
‐,O
initiates,O
‐,O
two,NUMBER
‐,O
phase,O
‐,O
3,NUMBER
‐,O
stud,O
‐,O
iesof,O
‐,O
investigational,O
‐,O
antiviral,O
‐,O
remdesivir,O
‐,O
for,O
‐,O
thetreatment,O
‐,O
of,O
‐,O
covid,O
‐,O
19,NUMBER
(,O
accessed,O
27,DATE
March,DATE
2020,DATE
),O
.,O
46,NUMBER
.,O
Medicines.org.uk,URL
.,O
Rib,O
‐,O
avirin,O
200,NUMBER
mg,O
film,O
‐,O
coated,O
product,O
/,O
7108,DATE
/,O
smpc,O
.,O
(,O
accessed,O
28,DATE
March,DATE
2020,DATE
),O
.,O
news,O
‐,O
releases,O
/,O
nih,O
‐,O
clinical,O
‐,O
trial,O
‐,O
remdesivir,O
‐,O
treat,O
‐,O
covid,O
‐,O
19,NUMBER
‐,O
begins,O
(,O
accessed,O
27,DATE
March,DATE
2020,DATE
),O
.,O
44,NUMBER
.,O
MedicineNet,O
.,O
Remdesivir,O
(,O
RDV,O
),O
:,O
experimental,O
remdesivir_rdv,O
(,O
accessed,O
27,DATE
March,DATE
2020,DATE
),O
.,O
48,NUMBER
.,O
Ritchie,PERSON
AI,O
and,O
Singanayagam,PERSON
A.,PERSON
Immuno,PERSON
suppression,O
for,O
hyperinflammation,O
in,O
COVID,O
‐,O
19,NUMBER
:,O
a,O
double,O
‐,O
edged,O
sword,O
?,O
Lancet,O
2020,DATE
;,O
395,NUMBER
:,O
1111,DATE
.,O
45,NUMBER
.,O
Zeng,PERSON
YM,PERSON
.,O
Xu,O
XL,O
.,O
He,O
XQ,O
.,O
et,O
al,O
.,O
Comparative,O
effec,O
‐,O
tiveness,O
and,O
safety,O
of,O
ribavirin,O
plus,O
interferonalpha,O
.,O
lopinavir,O
/,O
ritonavir,O
plus,O
interferon,O
‐,O
alpha,O
and,O
ribavirin,O
plus,O
lopinavir,O
/,O
ritonavir,O
plus,O
interferon,O
‐,O
healthcare,O
workers,O
against,O
COVID,O
‐,O
19,NUMBER
(,O
BRACE,O
),O
.,O
50,NUMBER
.,O
Mahase,PERSON
E.,PERSON
Covid,PERSON
‐,O
19,NUMBER
:,O
what,O
treatments,O
are,O
be,O
‐,O
ing,O
investigated,O
?,O
BMJ,O
2020,DATE
;,O
368,NUMBER
:,O
m1252,O
.,O
